WO2007103585A2 - Ventilator assist system and method to improve respiratory function - Google Patents

Ventilator assist system and method to improve respiratory function Download PDF

Info

Publication number
WO2007103585A2
WO2007103585A2 PCT/US2007/006135 US2007006135W WO2007103585A2 WO 2007103585 A2 WO2007103585 A2 WO 2007103585A2 US 2007006135 W US2007006135 W US 2007006135W WO 2007103585 A2 WO2007103585 A2 WO 2007103585A2
Authority
WO
WIPO (PCT)
Prior art keywords
diaphragm
electrode
ppmv
pressure
stimulation
Prior art date
Application number
PCT/US2007/006135
Other languages
French (fr)
Other versions
WO2007103585A3 (en
Inventor
Anthony R. Ignagni
Raymond P. Onders
Original Assignee
Synapse Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synapse Biomedical, Inc. filed Critical Synapse Biomedical, Inc.
Priority to EP07752811A priority Critical patent/EP1996284A2/en
Publication of WO2007103585A2 publication Critical patent/WO2007103585A2/en
Publication of WO2007103585A3 publication Critical patent/WO2007103585A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3601Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes

Definitions

  • the invention relates to apparatus and methods for supporting pulmonary function of patients in critical care settings.
  • a patient may need respiratory assistance as a result of disease and/or injuries of various kinds.
  • This need for respiratory assistance can be direct, especially when the injury or illness afflicts the patient's respiratory system.
  • patients in acute respiratory failure may need respiratory assistance.
  • the need for respiratory assistance can also be indirect, for example as during anesthesia.
  • the extent of respiratory assistance may encompass a range from facilitating spontaneous breathing to total control of breathing.
  • a mechanical ventilator that moves gas into the lungs of a patient using positive pressure to move air into the lungs may be used to provide respiratory assistance.
  • this respiratory assistance may be life saving, long-term use of a mechanical ventilator may not be ideal.
  • long-term mechanical ventilation use may result in weakening of the diaphragm of the patient because of disuse, and use of positive intrathoracic pressures may cause barotrauma, as well as provide inadequate ventilation of the posterior lobes of the lung, thereby possibly contributing to atelectasis, and generally compromising hemodynamics of the patient, which can have further deleterious consequences.
  • Embodiments of the invention include a method for supporting the respiration of patients that are typically in a critical care setting.
  • Embodiments of the invention make use of a system that includes an external stimulator and one or more electrodes adapted for implanting at one or more sites in the diaphragm.
  • the external stimulator is configured to stimulate the one or more electrodes independently, the one or more electrodes connected to the external simulator.
  • the method includes implanting the one or more electrodes in the diaphragm of the patient, initiating a breath, and stimulating the diaphragm with the one or more electrodes during a breath to increase tidal volume and/or to decrease maximal lung pressure during the breath, thereby improving respiratory compliance.
  • Embodiments of the invention include implanting the electrodes, or stimulating the implanted electrodes in such a way as to stimulate a specific portion of the diaphragm.
  • a specific portion of the diaphragm may, for example, include the left hemidiphragm or the right hemidiaphragm, or any particular portion of the left or right hemidiaphragm.
  • Such stimulation of a particular portion of a diaphragm may preferentially direct negative pressure to a particular portion of a patient's lungs, such as the right lung or the left lung.
  • a particular portion of a lung may include the lower or posterior portion of the lung.
  • a particular portion of a lung may suffer from atelectasis, or collapse. In such embodiments, directing negative pressure to the collapsed portion may cause a decrease in — or clearing of atelectasis.
  • the patient initiates, or attempts to initiate a breath, which is then sensed by the system, such that the patient-initiated breath is subsequently supported to completion by the respiratory support system.
  • Embodiments of the method include sensing the electrical activity in the diaphragmatic muscle through the electrodes of the system, which deliver electromyographic data to the system that are informative as to the diaphragmatic activity.
  • Other embodiments of the method include sensing the initiation of a breath with a sensor placed at the airway of the patient; in some embodiments this is a pressure sensor, in other embodiments it is a flow sensor.
  • the patient's breath is initiated by the external stimulator by way of stimulating the diaphragm.
  • the stimulator may provide a baseline breathing rate, in addition to supporting the breath through completion.
  • the ventilator initiates the breath and the external stimulator is used to reduce pressures, increase gas delivered, and/or direct gas flow to dependent portions of the lungs.
  • the stimulator may be synchronized in timing with the ventilator breathing cycle or electronically triggered by the ventilator or gas flow to assist the ventilator at a specific point in the breathing cycle.
  • Embodiments of the method include the stimulator being able to vary stimulation parameters with regard to any one or more signal parameters including pulse rate, pulse frequency, pulse amplitude, pulse duration, and pulse ramping.
  • the system may vary these parameters individually to each electrode, each electrode independently of others.
  • Application of the method beyond broadly improving respiratory complaints, may improve specific aspects of lung performance and patient health.
  • the method may, for example, improve any of hemodynamics venous return, cardiac output, alveolar ventilation, type 1 muscle fiber condition.
  • the method may decrease any of atlectasis, third spacing, time required for weaning from the PPMV, length of hospital stay, occurrence of pneumonia.
  • the method may condition Type I muscle fibers, and may stimulate the conversion of Type lib muscle fibers into Type I muscle fibers.
  • the method may support a regular breathing rate during sleep. Disturbed sleep can decrease or prevent occurrence of REM sleep, accordingly, uninterrupted sleep as supported by a regular breathing rate may increase the occurrence or duration of REM sleep. Loss of REM sleep is considered a causative factor in intensive care unit (ICU) psychosis. Accordingly, the method may alleviate the severity or development of ICU psychosis.
  • ICU intensive care unit
  • the method is applied to acute patients, who are expected to be weaned from the respiratory support system.
  • the patient has been previously supported by a positive pressure mechanical ventilator (PPMV), or by a combination of electrical diaphragm stimulation, per the presently described invention, and a PPMV.
  • PPMV positive pressure mechanical ventilator
  • the method includes the support of these patients by the above described system, after the PPMV support has been discontinued.
  • the electrodes may be implanted in the diaphragm any of several anatomical approaches and surgical methods.
  • the electrodes are implanted by insertion through the abdominal cavity, using either laparoscopic techniques or open surgical techniques.
  • the electrodes are implanted by insertion through the thoracic cavity, using either thoracoscopic techniques or open surgical techniques.
  • the electrodes are implanted in the diaphragm by way of insertion through natural orifices, using translumenal endoscopic techniques.
  • the system for the method may further include a positive pressure mechanical ventilator (PPMV), the method further comprising ventilating the patient with the PPMV.
  • PPMV positive pressure mechanical ventilator
  • the external stimulator and the PPMV are configured such that the external stimulator controls the PPMV, the method further comprising controlling the PPMV.
  • controlling the PPMV includes controlling operational parameters of PPMV, the parameters including any of breath rate, gas volume delivered per breath, or airway pressure behind delivered gas.
  • the external stimulator and the PPMV are configured such that the PPMV controls the external stimulator, the method further comprising controlling the external stimulator.
  • controlling the external stimulator includes triggering stimulator output at a time in relationship to the PPMV reaching peak pressure.
  • the method may include controlling the PPMV with a constraint of a maximal tidal volume, or it may include controlling the PPMV with a constraint of a maximal airway pressure
  • the airway pressure required by the PPMV is decreased by the concurrent diaphragmatic stimulation.
  • High airway pressure from a PPMV is associated with barotrauma to the lungs of such treated patients, accordingly, inclusion of diaphragm stimulation may reduce the risk of PPMV-associated barotrauma.
  • Embodiments of the invention also include a method for treating a patient with an atelectatic lung region with a system including an external stimulator and one or more electrodes implanted at one or more sites in the diaphragm, the external stimulator configured to stimulate the one or more electrodes independently, and a positive pressure mechanical ventilator (PPMV).
  • the method includes initiating a breath, ventilating the patient with the PPMV during the breath, stimulating the diaphragm with the one or more electrodes during the breath to increase tidal volume and/or to decrease maximal lung pressure during the breath.
  • the electrodes have been implanted or a stimulated such that they preferentially stimulate a specific portion of the diaphragm such that the volume of atelectatic region is expanded, thereby clearing the atelectatic region.
  • Embodiments of the invention also include an electrode suitable for temporary placement in tissue that includes a needle at a first end, a central portion including a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a second end including a deinsulated barb and a stop.
  • the stop comprises soft silicone.
  • the stop includes an absorbable suture material thermally bonded to the deinsulated coiled portion.
  • the needle is a break-away needle. Li some embodiments the straight insulated lead and the helically wound insulated lead are joined at a junction, and the electrode further includes a bonding material disposed at the junction to form a bond configured to prevent the helically wound lead from unwinding.
  • Embodiments of the invention further include a method of inserting an electrode suitable for temporary placement in a tissue site, the electrode including a needle at a first end, a central portion comprising a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a deinsulated barb and a stop at a second end.
  • the method includes inserting the electrode into a tissue site surface by the first end comprising the needle, and pulling the electrode through the tissue until the second end comprising the stop is at the tissue site surface.
  • Figure 1 is a block diagram of the external stimulator.
  • Figure 2 shows an example of an implantable electrode.
  • Figure 3 is a diagram illustrating a respiratory support system (system 1 ) including an external stimulator.
  • FIG 4 is a diagram illustrating a respiratory support system (system 2) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, but without a direct operable connection between the PPMV and the external stimulator.
  • system 2 including an external stimulator and a PPMV
  • an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, but without a direct operable connection between the PPMV and the external stimulator.
  • FIG. 5 is a diagram illustrating a respiratory support system (system 3) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, and with an operable connection between the PPMV and the external stimulator.
  • system 3 including an external stimulator and a PPMV
  • an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, and with an operable connection between the PPMV and the external stimulator.
  • Figure 6 is a block diagram showing three variations of respiratory support methods: (A) support with combination of PPMV and stimulator, with the stimulator initiating air flow into the lungs, (B) support with combination of PPMV and stimulator, with air flow being initiated by the PPMV, and (C) support by the stimulator alone, breath initiation either by the stimulator or by the patient, in which case the stimulator assists in completion of the breath.
  • Figure 7 is a diagram illustrating an example of coordinated timing of respiratory support as provided by a combination of an external stimulator and a positive pressure mechanical stimulator.
  • Figure 8 is a schematic graph that compares the relationship between internal lung pressure and lung volume over the course a breathing cycle, including an inhalation and an exhalation, in a patient supported by (A) positive pressure delivered by a positive pressure mechanical ventilator (PPMV) alone, and (B) the combination of negative pressure delivered by electrically stimulated diaphragm contraction and positive pressure delivered by a PPMV.
  • A positive pressure delivered by a positive pressure mechanical ventilator (PPMV) alone
  • PPMV positive pressure mechanical ventilator
  • Figure 9 shows a compliance pattern when respiration is supported by ventilation with a PPMV alone, without diaphragm stimulation.
  • Figure 10 shows a compliance pattern when respiration is supported by diaphragm stimulation alone (without PPMV ventilation).
  • Figure 11 shows a compliance pattern where diaphragm stimulation initiates a breath that is later supported by PPMV ventilation.
  • Figure 12 shows a compliance pattern where a breath is initiated by the PPMV, and is later supported by diaphragm stimulation.
  • Figures 13A — 13D provides views of airway pressure waveforms on positive pressure mechanical ventilator monitor under various conditions:
  • Figure 9A shows normal airway pressure waveform with ventilator only.
  • Figure 9B shows airway pressure with diaphragm stimulation starting approx. 1 sec into inspiration demonstrating ability to increase tidal volume and modulate airway pressure.
  • Figure 9C shows airway pressure with diaphragm stimulation started near beginning of inspiration and lasting for approx. 1 sec - demonstrating an ability to reduce airway pressure and maintain tidal volume.
  • Figure 78 shows airway pressure with stimulation in first inspiration and no stimulation in second inspiration.
  • Figure 10 shows airway compliance shift measured on positive pressure mechanical ventilator.
  • Components of the system for providing respiratory support by the methods described herein include an external stimulator for electrically stimulating a portion of the diaphragm of a patient, electrodes suitable for implanting in the diaphragm, and a positive pressure mechanical ventilator (PPMV).
  • PPMV positive pressure mechanical ventilator
  • the system includes only the stimulator and electrodes for respiratory support; other embodiments include the PPMV as well.
  • the electrical signal generator 110 shown in Figure 1 can be configured to generate pulses and/or signals that may take the form of sinusoidal, stepped, trapezoidal waveforms or other relatively continuous signals.
  • the electric signal generator 110 can include one or more channels that can independently control the amplitude, frequency, timing and pulse width of the corresponding electrodes connected thereto.
  • the electrical signal generator 110 can be an external signal generator that is electrically connected to or in electrical communication with the electrodes.
  • a suitable electrical signal generator is the NeuRx RA/4 stimulator that is manufactured by Synapse Biomedical, Inc. of Oberlin, Ohio.
  • the NeuRx RA/4 stimulator is a four-channel device with independent parameter programmability. It will be appreciated that since the NeuRx RA/4 stimulator has four channels, it has the capability to independently control up to four electrodes.
  • the electrical signal generator 110 can be an implantable signal generator.
  • One suitable example of a fully implanted signal generator is the "Precision" electrical signal generator available from Boston Scientific / Advanced Bionics.
  • the external stimulator 110 depicted in Figure 1 is comprised of several blocks to produce coordinated stimulus output.
  • the core of the device is a supervisory microcontroller 111 that coordinates parameter and sensed inputs, display, and stimulus / trigger outputs.
  • the stimulus and timing parameters are stored in non-volatile memory and are programmed, via a serial interface (not shown), specific to the respiratory support needs and electrode muscle recruitment characteristics of the particular patient.
  • the waveform generator 112 assembles the control signals from the microcontroller in the necessary waveform patterns to be output through the output stage signal drivers 113.
  • the microcontroller 111 receives power from a power supply 114.
  • the microcontroller 111 receives input of sensing information 115, impedance detection 116, stimulation parameters 117 and timing parameters 118.
  • the microcontroller 111 provides output to a trigger output 119 and an LCD 121, in addition to the waveform generator 112.
  • the output stage comprising drivers 113 also provide output to the impedance detector 116.
  • the drivers 113 provide output in the form of stimulation of the electrodes 120.
  • the resultant output is a capacitively coupled, current regulated biphasic waveform.
  • the microcontroller may be driven to send the control signals to the waveform generator from an external sensed source (either a digital level or analog signal, such as diaphragm EMG) or from internal timing that is based on the stored timing parameters.
  • the microcontroller may also be programmed to send out an analog or digital trigger signal to an external device based on a programmed sequence or event.
  • the electrical signal generator can supply the implantable electrodes with an electrical signal that serves as electrical stimulation to the respiratory system of the patient.
  • the electrical signal can be a capacitively-coupled, charge balanced, biphasic, constant current waveform with adjustable parameters as shown below in Table 1. It will be appreciated that the electrical signal can take the form of other waveforms for electrical stimulation such as monophasic or rectangular biphasic.
  • the stimulatory signal can be delivered to a variety of locations in the body of a patient to stimulate the respiratory system
  • the electrical stimulatory can be delivered to the diaphragm of the patient, through the electrodes, continuously or periodically.
  • the electrical stimulation can be delivered to the diaphragm of the patient at specified intervals per day (e.g. 5-6 sessions per day) for a certain period of time per interval (e.g. 5 minutes per session totaling about 25-30 minutes per day). It will be appreciated that the electrical stimulation can be delivered at different intervals depending on the needs of a particular patient.
  • the external electrical stimulator makes use of one or more intramuscular electrodes that are suitable for implanting into muscle tissue.
  • the intramuscular electrode can serve as a cathode.
  • the electrode is particularly adapted for temporary implantation.
  • Features of implantation that provide long term stability, as in a more permanent placement, tend to work against suitability for short-term placement. It is desirable for an electrode to be able to stably remain in the muscle tissue without migrating from the target implant site, and thus supplemental anchoring is generally helpful.
  • supplemental anchoring tends to complicate withdrawal.
  • tissue ingrowth as encouraged by the anchoring or by features of the electrode is desirable for stabilization and protecting the entry site, but such ingrowth can complicate removal.
  • the electrode may be treated as temporary by just abandoning its use, however that is unsatisfactory as presents risks to the patient of potential migration of unsecured portions, imaging artifact, or thermal/electrochemical effects if exposed to inappropriate MRI or diathermy.
  • the Peterson intramuscular electrode is a double helix wound from multistrand stainless steel wire insulated in fluoropolymer with a polypropylene core and barb.
  • the electrode can have a barb that is flattened and bent back along the line of the electrode, a polypropylene skirt, and a deinsulated coil under the skirt.
  • the electrode lead can terminate with a stainless steel pin crimped to the de-insulated end and back-filled with silicone adhesive for strain relief.
  • the intramuscular electrode can take the form of other shapes, sizes, and configurations, and can be made of other materials suitable for implantation into a patient.
  • FIG. 2 Another example of an electrode suitable for short-term implantation is shown in Figure 2.
  • This electrode 900 includes five primary elements: a deinsulated stimulating segment 902, a stop 904, a length of helically coiled insulated lead 906, a length of straight insulated lead 908, and a needle 910.
  • the stop may comprise a soft silicone plug.
  • the electrode is inserted, needle end first, into a target site, such as diaphramatic muscle, and pulled through until the stop at the opposite end is reached. Insertion in this manner results in the deinsulated stimulating segment ending up at the surface of the target muscle at the needle entry point.
  • the insulated lead is guided or tunneled to an appropriate exit site and the needle brought through the skin until the insulated coiled lead protrudes from the skin.
  • the junction of the coiled to straight segment of insulated wire is secured with silicone adhesive or other suitable material to maintain the coiled configuration as it is drawn through the muscle tissue and skin interface.
  • the coiled lead allows for tissue ingrowth at the skin exit site, thereby reducing the potential for infection entering and tracking along the lead.
  • the needle may be a breakaway type of needle that can be used to terminate the electrode into the appropriate connector or the straight length of lead may be cut, deinsulated, and terminated into an appropriate connector.
  • the stop maybe a small amount of silicon adhesive or a piece of absorbable suture thermally locked on to the deinsulated lead.
  • intramuscular electrode Another example of a suitable short term intramuscular electrode was disclosed in a U.S. Provisional Patent Application filed on Feb 5, 2007 by Ignagni, Enders, Gelbke, and Crish, entitled "Intramuscular Electrode".
  • this intramuscular electrode it comprises a single helix multistrand wire stainless steel wire insulated in fluoropolymer with a polypropylene core and barb.
  • Embodiments of this electrode either do not have the additional skirt of the Peterson electrode, or have a skirt of a lighter gauge polypropylene skirt than that of the Peterson intramuscular electrode, so that the electrode maybe withdrawn without the complication of significant ingrowth of tissue around the skirt.
  • the lead can be implanted under video guidance or direct visualization, using the attached needle to thread it into the diaphragm.
  • the needle and lead-in polypropylene core would be cut off after implantation.
  • the electrode would be withdrawn from the opposite end by straightening the helically wound wire and pulling on the polypropylene core and wire simultaneously. This would allow for the electrode to slide out from the tissue with minimal trauma and the polypropylene core would provide the mechanical support to prevent breakage of the wire in the body.
  • the electrodes can be implanted into target sites in the diaphragm of the patient.
  • the electrodes can be implanted into or adjacent the phrenic nerve motor points of the diaphragm (i.e., where the phrenic nerve enters the diaphragm) of the patient.
  • the phrenic nerve motor points of the diaphragm are locations in the diaphragm mat provide the greatest muscle fiber recruitment in response to an applied stimulation.
  • FIG. 3 is a diagram illustrating a respiratory support system (System 1) including an external stimulator but without a PPMV.
  • Figure 3 is a diagram illustrating an example system 300 for assisting breathing in a patient, the patient's lungs represented as 330.
  • the system 300 may include a stimulator 305 and one or more implantable electrodes 310 operably connected to the stimulator 305.
  • the stimulator 305 may be configured to emit a stimulatory signal that is communicated to the implantable electrodes 310 through an operable connection 335.
  • the stimulatory signal may be of a variety of types.
  • Example stimulatory signals may include electrical, magnetic, and other signals.
  • FIG 4 is a diagram illustrating a respiratory support system (System 2) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, but without a direct operable connection between the PPMV and the external stimulator.
  • Figure 4 is a diagram illustrating an example system 500 for assisting breathing in a patient.
  • the system 500 may include a stimulator 505 and one or more implantable electrodes 510 operably connected to the stimulator 505.
  • the system 500 may also include a mechanical ventilator 515.
  • the system 500 may also include an airflow measuring instrument or flow sensor 520.
  • the mechanical ventilator 515 may be configured to cycle a gas into the lungs 525 of a patient.
  • the mechanical ventilator 515 may also be configured to cycle the gas out of the lungs 525 of the patient.
  • the gas is delivered from the mechanical ventilator 515 to the lungs 525 of the patient through a patient circuit 530.
  • patient circuit 530 may include a set of flexible tubes.
  • one end of the patient circuit 530 may connect to the mechanical ventilator 515 and one end of the patient circuit 530 may connect to the patient through, for example, an endotracheal tube, a tracheostomy tube, a mask covering the patient's face, and the like.
  • the stimulator 505 may be configured to emit a stimulatory signal that is communicated to the implantable electrodes 510 through an operable connection 535.
  • the stimulatory signal may be of a variety of types.
  • Example stimulatory signals may include electrical, magnetic, and other signals.
  • An example airflow measuring instrument 520 of flow sensor may interact with the system 500 along the ventilation breathing circuit ⁇ e.g. , between the mechanical ventilator 515 and the lungs 525 of the patient).
  • the airflow measuring instrument 520 generally is capable of sensing and/or measuring inspiratory and/or expiratory air flow in the ventilatory breaming circuit or cycle ⁇ e.g., measuring air flow in the ventilatory breathing circuit).
  • One type of airflow measuring instrument 520 may be a pneumotachometer.
  • the airflow measuring instrument 520 may be capable of emitting a signal or facilitating an associated or separate logic and/or software, for example, of emitting a signal related to the sensed or measured airflow.
  • This signal may be communicated or transmitted, directly or indirectly, to the mechanical ventilator 515.
  • This signal may be communicated, for example, via an operable connection 540 between the airflow measuring instrument 520 and the mechanical ventilator 515.
  • the signal from the airflow measuring instrument 520 may also or alternatively be communicated or transmitted, directly or indirectly, to the stimulator 505.
  • This signal may be communicated, for example, via an operable connection 545 between the airflow measuring instrument 520 and the stimulator 505.
  • the signals may facilitate timing or synchronization of a ventilatory cycle with delivery of a stimulatory signal or of delivery of a stimulatory signal with a ventilatory cycle.
  • the signals may also or alternatively facilitate adjustment or variability in one or both of the ventilatory cycle and stimulatory signal.
  • FIG. 5 is a diagram illustrating a respiratory support system (System 3) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, and with an operable connection between the PPMV and the external stimulator.
  • Figure 5 is a diagram illustrating an example system 700 for assisting breathing in a patient.
  • the system 700 may include a stimulator 705 and one or more implantable electrodes 710 operably connected to the stimulator 705.
  • the stimulator 705 maybe configured to emit a stimulatory signal that is communicated to the implantable electrodes 710 through an operable connection 740.
  • the system 700 may also include a mechanical ventilator 715.
  • the mechanical ventilator 715 may be configured to cycle a gas into and/or out of the lungs 730 of a patient via a patient circuit 735.
  • the system 700 may also include an airflow measuring instrument 720.
  • the airflow measuring instrument 720 may be capable of sensing and/or measuring inspiratory and/or expiratory air flow in the ventilatory breathing circuit.
  • the airflow measuring instrument 720 or an example logic associated with or separate from the airflow measuring instrument 720, may be capable of emitting a signal related to the sensed or measured airflow. This signal may be communicated or transmitted, directly or indirectly, to the mechanical ventilator 715. This signal may be communicated, for example, via an operable connection 745 between the airflow measuring instrument 720 and the mechanical ventilator 715.
  • the system 700 may also include a breathing sensor and control circuit 725.
  • the breathing sensor and control circuit 725 can be configured to detect and/or determine certain breathing attributes of the patient (e.g., the inspiration phase of a breath, the duration of the inspiration phase, the exhalation phase of a breath, the duration of the exhalation phase, tidal volume, airway pressures, and/or flow rate). These breathing attributes may be communicated to the breathing sensor and control circuit 725 via, for example, an operable connection 750 between the airflow measuring instrument 720 and the breathing sensor and control circuit 725.
  • the breathing sensor and control circuit 725 may process these signals and transmit them to the stimulator 705, for example, via an operable connection 755 between the breathing sensor and control circuit 725 and the stimulator 705.
  • the system 700 may also include an operable connection 760 between the mechanical ventilator 715 and the breathing sensor and control circuit 725. The operable connection 760 may facilitate, for example, timing of a ventilatory cycle with delivery of a stimulatory signal.
  • the system 700 can include a pressure gauge (not shown) and gas meter (not shown), provided along the ventilator breathing circuit, to measure the pressure and/or gas- related parameters of the patient's breathing.
  • a physiological measurement unit can be connected to the patient to measure certain physiological parameters such as blood pressure, blood values, body temperature, etc. These measurements may be used by the system 700 to adjust or modify parameters of ventilation controlled by the mechanical ventilator 715 and or parameters of the stimulatory signal delivered by the stimulator 705.
  • Exemplary methods may be better appreciated with reference to the flow diagram of Figure 6 which shows three variations of respiratory support methods: (6A) support with combination of PPMV and stimulator, with the stimulator initiating air flow into the lungs, (6B) support with combination of PPMV and stimulator, with air flow being initiated by the PPMV, and (6C) support by the stimulator alone, breath initiation either by the stimulator or by the patient, in which case the stimulator assists in completion of the breath.
  • Methods shown in 6 A and 6B thus depict respiration support with the combination of electrical stimulation of diaphragm contraction that is further supported by positive airway pressure from the PPMV.
  • the stimulator initiates the breath, and the PPMV provides supplemental gas under pressure to the patient as needed.
  • the breath is initiated by the PPMV initiating a breath by flowing air into the lungs of the patient.
  • the patient may initiate a breath that is detected by a gas flow detector on the PPMV, as which point the PPMV provides gas flow to support continuation of the breath.
  • the breath is not initiated by the external stimulator, but the stimulator does activate after the breath is initiated independently of it, from which point forward the stimulator supports the breath by the diaphragm creating negative pressure within the chest.
  • the electrode stimulation being to a specific portion of the diaphragm, the gas flow, also being supported by the PPMV is directed to a specific portion of the lung.
  • the respiration is supported by the electrical stimulation of the electrodes, without participation of the PPMV.
  • the breath is typically initiated by the patient volitionally, and the diaphragm stimulation directs the breath by stimulating a specific portion of the diaphragm, which directs airflow toward a specific portion of the lung.
  • the stimulator may initiate the breath, and then further support it as described.
  • This invention generally relates to manipulating respiratory compliance in patients in need of respiratory support, manipulating compliance in specific portions of the lung, and manipulating compliance toward specific therapeutic benefits. Compliance is manipulated or modulated through the coordinated activity of two therapeutic approaches.
  • a first approach is by electrical stimulation of the diaphragm (diaphragm pacing), which supports respiration by way of generating negative intrathoracic pressure that expands lung volume by an external pull.
  • Embodiments of the invention actually include therapy by this approach alone; other embodiments simultaneously include the second approach as well.
  • the second approach is by way of a positive pressure mechanical ventilator, which supports respiration by generating a positive pressure within the lungs that expands lung volume with an outward push.
  • the positive pressure approach to respiratory support is quite powerful, as the mechanical ventilator can easily provide sufficient pressure to expand lung volume.
  • This approach by itself has some limitation.
  • the first limitation is that pressure, while effective in expanding lungs, can also damage lung tissue if it is too high, and used for too long a period of time.
  • the second limitation is that positive pressure delivered by a PPMV, by itself, cannot be specifically directed to a portion of a lung.
  • Diaphragm stimulation as a base therapeutic approach provides respiratory support that does not stress lung tissue with high internal pressure, and further, provides a capability to steer volume expansion to particular regions of lung that are in particular need of expansion, such a an atelectatic region.
  • the combining of the two therapeutic approaches not only decreases the need for high airway pressure from the ventilator, but also adds a steering to the moderated internal pressure that the ventilator does provide.
  • a number of aspects of broader hemodynamic health are provided to the patient by the generally improved respiratory compliance.
  • Embodiments of the described invention provide a system and methods to support the respiration of patients in a critical care setting. Such patients are typically in acute need of respiratory support, but they are anticipated to be able to recover from the need for respiratory support. These patients are thus not considered to be in need of chronic support, and accordingly, the electrodes used in this therapeutic method are implanted in the diaphragm in a manner that may be considered temporary.
  • the invention is not limited to acute patients, and may in some instances be appropriate for longer term or chronic management of respiratory disease.
  • the system includes an external electrical stimulator and one or more electrodes adapted to be temporarily placed in the diaphragm of a patient, the electrodes being connected to and under the control of an external stimulator.
  • the external stimulator is configured to be able to stimulate each of the electrodes independently of each other.
  • the method by which respiration is supported by electrical stimulation of the diaphragm includes implanting the one or more electrodes in the diaphragm of the patient, initiating a breath, and stimulating the diaphragm with the one or more electrodes during a breath to increase tidal volume and/or to decrease maximal lung pressure during the breath, thereby improving respiratory compliance.
  • the breath may be initiated either by the patient or by the respiratory support system.
  • the system may further include a positive pressure mechanical ventilator.
  • Basics of the system and method of respiratory support by diaphragmatic stimulation is provided as a stand alone therapy (Le, in the absence of positive pressure support) is not substantially changed by the inclusion of ancillary positive pressure support, and thus will be described first as a stand alone therapy, to be followed by particulars that come with the inclusion of positive pressure support.
  • a breath may be understood as a breathing cycle that includes a single inspiration phase followed by a single exhalation.
  • a breath or an attempted breath may be initiated the patient, and the patient-initiated breath is then supported at least in some portion through the cycle by diaphragm stimulation.
  • the breath is initiated by the diaphragm stimulation, and then further supported at least through a portion of the cycle by further or continued diaphragm stimulation.
  • the electrical stimulation of the diaphragm not only supports the breath, but it also determines the breathing rate.
  • the system then supports the breath through independent stimulation of electrodes, through variation in various signal parameters as described further below, and through variable timing throughout the breath cycle, whether such stimulation is at the beginning, middle, or end of the cycle, or throughout the cycle.
  • breath initiation is sensed by the system through the electrodes themselves.
  • breath initiation whether it would ultimately be successful without respiratory support or not, manifests as electrical activity in the diaphragmatic muscle.
  • electrical activity is be captured by electrodes in the form of electromyographic data, which are processed by the microcontroller of the system ( Figure 1), and interpreted as a breath initiation attempt.
  • the electrodes may be implanted in the diaphragm by any of several anatomical approaches and by various surgical methods and tools.
  • the electrodes are implanted by insertion through the abdominal cavity, using either laparoscopic techniques or open surgical techniques.
  • the electrodes are implanted by insertion through the thoracic cavity, using either thoracoscopic techniques or open surgical techniques.
  • the electrodes are implanted in the diaphragm by way of insertion through natural orifices, using translumenal endoscopic techniques.
  • the placement of electrodes may be done under direct visualization (e.g. , open surgical technique) or with video observation through a surgical camera. Location of electrode placement may be assisted with electrical stimulation mapping of the diaphragm to identify the phrenic nerve motor point or specific branches. It may be desirable to identify specific branches so as to recruit the largest anatomical surface area ⁇ e.g. anterior or posterior) portions of the diaphragm. Mapping may be done in an open procedure, thoracoscopically, or laparoscopically, or endoscopically (using a transgastric approach). Prior laparoscopic and endoscopic techniques have been described in associated patents filings (U.S. Application No. 60/597440, U.S. Pat. No. 5,472,438, and U.S.
  • Patent Published Application No. 2005/0107860 are incorporated and enhanced with this invention. While direct visualization of the phrenic nerve may be accomplished with an open thoracic or thoracoscopic approach, it may be desirable, as provided by embodiments of this invention, to verify the placement location with electrical stimulation mapping of the diaphragm.
  • Electrodes may be implanted in the diaphragm muscle with an electrode delivery instrument; one exemplary instrument is described in U.S. Patent No. 5,797,923.
  • Another method as provided by embodiments of this invention, include the use of an apparatus to puncture through the skin and provide a channel for introduction of a needle loaded with a barbed intramuscular electrode that may be inserted into the diaphragm under thoracoscopic, laparoscopic, or endoscopic visualization. If implanted during an open procedure the intramuscular electrode maybe sewn into the diaphragm using a special electrode that is incorporated into this invention.
  • Embodiments of the method include the targeting to specific portions of the diaphragm to stimulate. Such targeting may be brought about by the selection of the diaphragm sites in which the electrodes are implanted, and it may also include the stimulation of a subset of implanted electrodes that are located in a diaphragm site of interest.
  • a specific portion of the diaphragm may, for example, include the left hemidiphragm or the right hemidiaphragm, or any particular portion of the left or right hemidiaphragm.
  • Stimulation of a particular portion of a diaphragm, the right or left hemidiphragm, for example, has the effect of directing or steering negative pressure to a particular portion of a patient's lungs, such as the right lung or the left lung, respectively.
  • a particular portion of a lung may include the lower or posterior portion of the lung.
  • a particular portion of a lung may suffer from atelectasis, or collapse.
  • directing negative pressure to the collapsed portion may cause a decrease in or clearing of atelectasis.
  • some embodiments of the method include the use of a system that includes a positive pressure mechanical ventilator (PPMV) supplying positive airway pressure to the lungs in addition to the external stimulator stimulating the diaphragm to supply negative pressure external to the lungs.
  • the external stimulator generally controls the operation of the mechanical ventilator, as the two components are configured in a master - slave relationship.
  • the positive pressure mechanical ventilator may either be invasive ⁇ e.g., endotracheal intubation or tracheostomy) or non-invasive ⁇ e.g., mask ventilation).
  • the external stimulator may control the operation of PPMV with regard to any of the breath rate, the gas volume delivered per breath, or the airway pressure behind delivered gas.
  • the PPMV can be set at a back-up rate so that the breathing rate is controlled by the stimulator such that either delivered gas volume or delivered airway pressure is controlled during a breath cycle.
  • the PPMV may be controlled in such a way that maximal tidal volume is a constraint.
  • the PPMV may also be controlled such that maximal airway pressure is a constraint.
  • the PPMV may be set in assist mode, where it assists within a breath cycle initiated either by the patient or by a diaphragm contraction that is stimulated by electrodes, or, alternatively the PPMV may be directly controlled by the external stimulator so that an inspiration initiated by the external stimulator triggers the PPMV to deliver supplemental gases.
  • the stimulator may be configured to provide stimulation at the beginning, middle, or end of an inspiration cycle or coincidental with the entire cycle.
  • the level of stimulation provided may be modulated during the cycle or remain constant (whether the cycle is initiated by the external stimulator or the PPMV).
  • the stimulation may be delivered to all implanted electrodes simultaneously, to electrodes grouped by hemi-diaphragm, or to individual electrodes to preferentially contract portions of a diaphragm.
  • the timing between stimuli delivered to specific electrodes may be sequenced so that the stimuli are delivered simultaneously, spaced throughout the stimulus cycle, or anywhere in between.
  • FIG. 7 is a diagram illustrating one example of timing between mechanical ventilation and a stimulatory signal 400.
  • the diagram illustrates initiation of a stimulatory signal 405 with the beginning of inspiration 410 that is provided or assisted by a mechanical ventilator.
  • the diagram also illustrates an increase in the level of the stimulatory signal 415 later in the inspiratory cycle 420. This increased stimulatory signal 415 may facilitate moving gases into the lower lobes of the lungs of the patient, for example.
  • the profile of generation or delivery of the stimulatory signal in relation to a ventilatory cycle may be modified for individual patients. These modifications may include, but are not limited to, the magnitude of the stimulation, the timing of the stimulation relative to the ventilatory cycle, and the rate ⁇ e.g., ramping) at which the stimulatory signal is changed during the cycle. These modifications maybe implemented or facilitated by, for example, software or logic. [00071] It will also be appreciated that stimulation of the diaphragm of the patient may not be synchronized with breathing or attempts at breathing made by the patient and, thus, can be applied during any portion of a breath or ventilatory cycle.
  • Respiratory compliance refers to the relationship between lung volume and air pressure within the lung.
  • Optimal lung function is favored good compliance, Le., by a high degree of responsiveness of a change in lung volume in response to change in pressure, as an increase in volume opens alveolae and creates greater lung surface area for gas exchange. Poor compliance impedes the amount of gas exchanged during a breath, which has a number of deleterious and well known consequences.
  • Compliance involves a quality of lung tissue and resistance of airways that is associated with the state of health and integrity in a general sense, but is also a functional quality that can be manipulated or modulated by diaphragm stimulation.
  • FIG. 8A depicts the dynamics of pressure and volume in a lung that is being supported by positive pressure mechanical ventilation (PPMV) alone and by a combination of diaphragm stimulation and PPMV.
  • PPMV positive pressure mechanical ventilation
  • FIG. 9 depicts the dynamics of pressure and volume in a lung that is being supported by positive pressure mechanical ventilation (PPMV) alone and by a combination of diaphragm stimulation and PPMV.
  • Figure 8A depicts lung volume as a function of air pressure within the lung through a breath cycle of a single inspiration and a single exhalation.
  • Pressure is shown on the X-axis, and is relative to atmospheric pressure, atmospheric pressure representing zero on the X-axis.
  • the volume is shown on the Y-axis, and is shown in terms of the increase in volume over the functional reserve capacity of the lung, ⁇ .e., the volume at the low point of a normal exhalation.
  • the maximal volume achieved during a normal inhalation is termed the tidal volume.
  • the time course of the volume/pressure ratio of a lung during a breath that is supported by both PPMV and diaphragm- stimulated intrathoracic negative pressure may begin with an immediate drop in pressure if the driving force from the diaphragm stimulation either precedes or is greater than the positive pressure from the PPMV.
  • This pressure drop is due to the stimulated contraction of the diaphragm.
  • air may be flowing into the lung from the PPMV, and at a certain point that PPMV driving force from the PPMV becomes greater than that of the diaphragm stimulation the pressure reverses while the inflow of air continues.
  • the pressure begins to rise, the pressure crosses the baseline level, and climbs to the same peak level depicted in figure 8B.
  • the pressure may drop from the peak pressure and be held at a plateau to sustain the given volume. As the pressure falls below the elastic force of the lungs and chest the volume falls steadily back to the origin during exhalation.
  • the specific form of the curve depicted in figure 8B varies with timing of the stimulation, and according to other stimulatory parameters, but the point of this depiction is that under conditions of figure 8B, the lung is more compliant, and for a given maximal volume, the lung tissue is exposed to a significantly lower pressure.
  • Lung compliance may be improved, for example, by modifying diaphragm stimulation parameters to elicit a higher change in tidal volume with each inspiration or by maintaining tidal volume while reducing the delivered pressures.
  • Compliance may be modified, preferentially, on the right or left lobes of the lungs, by separately controlling stimulation levels to the right or left hemi- diaphragm to pull gas to an otherwise unventilated region. This preferential directing of internal gas movement by way of controlling negative intrathoracic pressure can be used to reduce or clear an atelectic region. Contraction of the diaphragm also preferentially pulls the gas to the posterior or dependent lobes of the lungs and helps to prevent pneumonias.
  • the addition of negative pressure during the inspiration cycle may also be used to reduce the intra-thoracic pressure and thereby improve the venous return. This has the effect of increasing the cardiac stroke volume and cardiac output, thus improving the patient's hemodynamics. This should also improve any third-spacing that may be a result of PPMV.
  • the external stimulator may be triggered by the cardiac cycle to provide optimal timing between the left ventricular filling and the contraction of the diaphragm.
  • the method may, for example, improve any of hemodynamics venous return, cardiac output, alveolar ventilation, type 1 muscle fiber condition.
  • the method may decrease any of atlectasis, third spacing, time required for weaning from the PPMV, length of hospital stay, occurrence of pneumonia.
  • the method may condition Type I muscle fibers, and may stimulate the conversion of Type lib muscle fibers into Type I muscle fibers.
  • the method may support a regular breathing rate during instances of hypopnea or apneas, particularly during sleep. Disturbed sleep can decrease or prevent occurrence of REM sleep, accordingly, uninterrupted sleep as supported by a regular breathing rate may increase the occurrence or duration of REM sleep. Loss of REM sleep is considered to be a causative or risk factor for intensive care unit (ICU) psychosis. Accordingly, the method may alleviate the severity or development of ICU psychosis.
  • ICU intensive care unit
  • Figures 9 — 12 is a series of specific comparisons of compliance patterns that manifest under various respiratory support regimens as provided by diaphragm stimulation or PPMV support, alone and in combination.
  • an upper graph A shows a time sequence of activity of both the ventilator (above, if present) and the external electrical stimulation (below, if present)
  • a lower graph B shows the same data displayed as an graph of volume as a function of pressure.
  • a pattern ( Figure 9) conventional ventilator compliance pattern without diaphragm stimulation, a compliance pattern ( Figure 10) with diaphragm stimulation only, a compliance pattern ( Figure 11) the breath is initiated by stimulation and is further supported by the PPMV 5 and a compliance pattern ( Figure 12) where the PPMV initiates the breath and diaphragm stimulation further supports the breath.
  • Figure 9 shows a compliance pattern when respiration is supported by ventilation with a PPMV alone, without diaphragm stimulation.
  • the ventilator pressure/flow starts to increase during inspiration (701) the volume build slowly increases (702).
  • the airflow resistance decreases and the rate of volume to pressure increase becomes greater until the peak pressure (704) is reached.
  • the plateau pressure is maintained (705) and the volume is held (706).
  • the volume is maintained (706) until the pressure falls below the elastic force of the respiratory system and an exhalation occurs (708).
  • Figure 10 shows a compliance pattern when respiration is supported by diaphragm stimulation alone (without PPMV ventilation).
  • the stimulation is initiated (711) causing a negative pressure increase with volume drawn into the lungs (712).
  • the peak stimulation level (714) is reached the peak pressure (713) is obtained and the volume held (715).
  • the stimulation is turned off or ramped down (716) the inspired volume will be exhaled (717).
  • Figure 11 shows a compliance pattern where diaphragm stimulation initiates a breath that is later supported by PPMV ventilation.
  • the stimulation initiates the breath (721) causing a negative pressure with increasing volume (722). If the ventilator pressure exceeds the negative pressure force from the stimulation (723) the pressure curve will become positive with increasing volume (724). If the ventilator pressure is less than the negative pressure force from the stimulation (723) the pressure curve will remain negative with increasing volume (not shown). After the plateau pressure and maximum volume (725) is reached the exhalation phase may commence. The pressure is decreased until the elastic recoil of the lungs and chest causes exhalation (727). The pressure may become negative again depending on the relative force from the stimulation to the PPMV (726).
  • Figure 12 shows a compliance pattern where a breath is initiated by the PPMV, and is later supported by diaphragm stimulation.
  • the PPMV initiates the breath (731) causing a positive pressure with increasing volume (732). If the ventilator pressure is less than the negative pressure force from the stimulation (733) the pressure curve will become negative with increasing volume (734). If the ventilator pressure exceeds the negative pressure force from the stimulation (733) the pressure curve will remain positive with increasing volume (not shown). After the plateau pressure and maximum volume (735) is reached the exhalation phase may commence. The pressure is decreased until the elastic recoil of the lungs and chest causes exhalation (737). The pressure may become positive again depending on the relative force from the stimulation to the PPMV (736).
  • FIGs 13A - 9I> show screenshots of patient data collected from a study in which positive pressure ventilation and diaphragm stimulation were variously applied.
  • a peak airway pressure (P PEAK ) of 17 cm H 2 O and mean airway pressure (P M ) of 5 cm H 2 O is reached under the ventilator only conditions.
  • Figure 9B shows airway pressure with diaphragm stimulation starting approximately 1 sec into inspiration, thus demonstrating ability to increase tidal volume and modulate airway pressure.
  • the airway pressures and tidal volumes would be specifically controlled to recruit collapsed lung units (e.g. decrease atelectasis).
  • V ⁇ 0.62 liters
  • the peak airway pressure needed to overcome any large airway resistances may be applied and the plateau pressure (P PLAT ) reduced or eliminated thus avoiding overdistension of the lungs.
  • P PLAT plateau pressure
  • FIG. 13C top left shows airway pressure with diaphragm stimulation started near the beginning of inspiration and lasting for approximately. 1 sec, thus demonstrating ability to reduce airway pressure and maintain tidal volume.
  • Figure 13D shows airway pressure with stimulation in first inspiration and no stimulation in second inspiration.
  • Figure 14 demonstrates the addition of synchronous breaths to a volume ventilator and the effect upon respiratory system compliance (C RS ).
  • C RS respiratory system compliance
  • Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease) is a condition leading to fatal motor neuron degeneration. Muscular weakness typically progresses at the rate of 1.8% to 3.5% per month. When the muscle deterioration reaches the diaphragm, the patient develops hypercarbic respiratory failure, leading to death. ALS patients may experience different rates of decline in their left and right hemidiaphragms.
  • a mechanical ventilator also known as positive pressure mechanical ventilator or PPMV
  • PPMV positive pressure mechanical ventilator
  • PPMV positive pressure mechanical ventilator
  • PPMV thoracic pressure caused by PPMV can lead to decreased cardiac output and barotrauma, with possible posterior lobe collapse, atelectasis and/or pneumonia. Further, many ALS patients do not tolerate non-invasive PPMV, due to the bulbar symptoms of the disease, and most of them do not accept invasive PPMV.
  • diaphragm pacing can induce new nerve branching in the diaphragm, counteract muscle atrophy and slow the decline of forced vital capacity (FVC) in ALS patients.
  • FVC forced vital capacity
  • Diaphragm pacing can reduce patient airway pressure, increase overall ventilation, increase diaphragm strength, maintain Type 1 diaphragm muscle fibers, improve cardiac output and provide increased posterior lobe ventilation.
  • Electrodes were implanted laparoscopically in the patients' two hemidiaphragms at motor points determined during an earlier mapping procedure, and stimulation was provided in 30 minute sessions three to five times per day. Stimulation was provided at 12 Hz, with the pulse width and amplitude as much as the patient could tolerate (typically around 10 ma, pulse width 150 ms) to provide the patient with 8 — 15 breaths per minute. Patients were permitted to increase stimulation utilization over time if desired. In addition to measuring FVC and other lung capacity parameters, diaphragm thickness was measured ultrasonically, blood gases were sampled, and patient quality of life information was surveyed.
  • the diaphragm pacing system used for stimulation can provide different stimulation signals to each electrode in each hemidiaphragm. Stimulation parameters can be varied by amplitude, frequency, rate, pulse width and pulse modulation. Diaphragm muscle mass increased over the course of the diaphragm pacing as shown in the Table 2 below:
  • ALSFRSr ALS Functional Rating Scale
  • Diaphragm pacing can also be used together with non-invasive mechanical ventilation in the ALS patients to decrease peak airway pressure and increase tidal volume, making the intervention of non-invasive PPMV tolerated by a greater portion of ALS patients. This intervention would also increase respiratory compliance, reduce atelectatic lung regions and thereby reduce the risks of acute respiratory failures.
  • a volume ventilator mode may be used to provide ventilatory needs.
  • the diaphragm pacing may be used to assist in this case to (1) preferentially ventilate the dependent portions of the lungs to avoid atelectasis, (2) reduce the applied pressures, and (3) reduce the work of breathing by increasing the respiratory system compliance, as outlined below.
  • the stimulation may be applied after the volume delivery commences (after the peak pressure but prior to completion of the positive gas flow) to draw the delivered air to the posterior lobes.
  • higher stimulus parameters may be used, if needed, as any discomfort from the stimulus would not be felt by the patient.
  • the stimulation may initiate coincidental to the ventilated breath to reduce peak airway pressure or subsequent to the peak to reduce the plateau pressure.
  • the stimulation could be ramped on at a rate (over the gas delivery) to avoid an inrush of negative inspiratory force and stacked breaths.
  • the stimulation may be applied at a lower level (e.g. amplitude of 10mA as opposed to 25mA) at the beginning of the ventilatory cycle to reduce initial peak pressures or throughout the gas delivery to reduce peak and plateau pressure while maintaining the tidal volume (as in figure 3C) thus increasing the respiratory system compliance.
  • a lower level e.g. amplitude of 10mA as opposed to 25mA
  • the stimulation can be used to provide the primary ventilatory support with the ventilator as a backup.
  • the diaphragm stimulation would be set to obtain the desired volume at stimulation values mat the patient could tolerate.
  • the stimulus may be set in a range of 10 - 25mA at a pulse duration of lOO ⁇ s and pulse frequency of 10 — 15ELz. If adequate ventilation is obtained the ventilator would be set to provide only backup to the stimulated support. If adequate volumes are not obtained the ventilator pressure would be increased until adequate volumes are obtained. This support could be done with endotracheal or mask ventilation.

Abstract

Systems and methods are provided to improve respiratory function. Systems include an external electrical stimulator coupled to electrodes that stimulates diaphragm contraction and may optionally include a positive pressure mechanical ventilator. The system further includes an electrode suitable for temporary implantation. Electrical stimulation is provided to specific portions of the diaphragm, such as one hemidiaphragm preferentially over another. By preferentially contracting one hemidiaphragm, a specific portion of a lung may be expanded such as a posterior portion. By the provision of the negative intrathoracic pressure from diaphragm contraction, greater expansion of specific portion of lung is achieved in relationship to air pressure within the lung. Supplementation of stimulated diaphragm contraction with positive pressure driven air flow from a PPMV directs the air flow to specific portions of the lung. Such portion may include a posterior portion of a lung, and may cause a clearing of atelectasis in that portion.

Description

VENTILATORY ASSIST SYSTEM AND METHODS TO IMPROVE RESPIRATORY FUNCTION
REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Applications No. 60/767,201 which, was filed on March 9, 2006, No. 60/861,568 which was filed on November 28, 2006, and No. 60/872,265 which was filed on December 1, 2006, all applications by inventors Ignagni and Onders. This application is also related to U.S. application no. 10/897,685, filed on July 23, 2004, and which was published as U.S. Pub. No. US 2005/0021102 on January 27, 2005. All of the aforementioned applications are hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] The invention relates to apparatus and methods for supporting pulmonary function of patients in critical care settings.
BACKGROUND OF THE INVENTION
[0003] A patient may need respiratory assistance as a result of disease and/or injuries of various kinds. This need for respiratory assistance can be direct, especially when the injury or illness afflicts the patient's respiratory system. In one example, patients in acute respiratory failure may need respiratory assistance. The need for respiratory assistance can also be indirect, for example as during anesthesia. Typically, the extent of respiratory assistance may encompass a range from facilitating spontaneous breathing to total control of breathing.
[0004] A mechanical ventilator that moves gas into the lungs of a patient using positive pressure to move air into the lungs may be used to provide respiratory assistance. Although this respiratory assistance may be life saving, long-term use of a mechanical ventilator may not be ideal. For example, long-term mechanical ventilation use may result in weakening of the diaphragm of the patient because of disuse, and use of positive intrathoracic pressures may cause barotrauma, as well as provide inadequate ventilation of the posterior lobes of the lung, thereby possibly contributing to atelectasis, and generally compromising hemodynamics of the patient, which can have further deleterious consequences.
SUMMARY OF THE INVENTION
[0005] Embodiments of the invention include a method for supporting the respiration of patients that are typically in a critical care setting. Embodiments of the invention make use of a system that includes an external stimulator and one or more electrodes adapted for implanting at one or more sites in the diaphragm. The external stimulator is configured to stimulate the one or more electrodes independently, the one or more electrodes connected to the external simulator. The method includes implanting the one or more electrodes in the diaphragm of the patient, initiating a breath, and stimulating the diaphragm with the one or more electrodes during a breath to increase tidal volume and/or to decrease maximal lung pressure during the breath, thereby improving respiratory compliance.
[0006] Embodiments of the invention include implanting the electrodes, or stimulating the implanted electrodes in such a way as to stimulate a specific portion of the diaphragm. Such a specific portion of the diaphragm may, for example, include the left hemidiphragm or the right hemidiaphragm, or any particular portion of the left or right hemidiaphragm. Such stimulation of a particular portion of a diaphragm may preferentially direct negative pressure to a particular portion of a patient's lungs, such as the right lung or the left lung. A particular portion of a lung may include the lower or posterior portion of the lung. In some embodiments, a particular portion of a lung may suffer from atelectasis, or collapse. In such embodiments, directing negative pressure to the collapsed portion may cause a decrease in — or clearing of atelectasis.
[0007] In some embodiments of the method, the patient initiates, or attempts to initiate a breath, which is then sensed by the system, such that the patient-initiated breath is subsequently supported to completion by the respiratory support system. Embodiments of the method include sensing the electrical activity in the diaphragmatic muscle through the electrodes of the system, which deliver electromyographic data to the system that are informative as to the diaphragmatic activity. Other embodiments of the method include sensing the initiation of a breath with a sensor placed at the airway of the patient; in some embodiments this is a pressure sensor, in other embodiments it is a flow sensor.
[0008] In other embodiments, the patient's breath is initiated by the external stimulator by way of stimulating the diaphragm. In such embodiments, the stimulator may provide a baseline breathing rate, in addition to supporting the breath through completion.
[0009] In other embodiments, the ventilator initiates the breath and the external stimulator is used to reduce pressures, increase gas delivered, and/or direct gas flow to dependent portions of the lungs. In such embodiments, the stimulator may be synchronized in timing with the ventilator breathing cycle or electronically triggered by the ventilator or gas flow to assist the ventilator at a specific point in the breathing cycle.
[00010] Embodiments of the method include the stimulator being able to vary stimulation parameters with regard to any one or more signal parameters including pulse rate, pulse frequency, pulse amplitude, pulse duration, and pulse ramping. The system may vary these parameters individually to each electrode, each electrode independently of others. [00011] Application of the method, beyond broadly improving respiratory complains, may improve specific aspects of lung performance and patient health. The method may, for example, improve any of hemodynamics venous return, cardiac output, alveolar ventilation, type 1 muscle fiber condition. The method may decrease any of atlectasis, third spacing, time required for weaning from the PPMV, length of hospital stay, occurrence of pneumonia. The method may condition Type I muscle fibers, and may stimulate the conversion of Type lib muscle fibers into Type I muscle fibers.
[00012] Some patients are at risk for the development of central hypoventilation syndrome (CHS), in such patients, the method may support a regular breathing rate during sleep. Disturbed sleep can decrease or prevent occurrence of REM sleep, accordingly, uninterrupted sleep as supported by a regular breathing rate may increase the occurrence or duration of REM sleep. Loss of REM sleep is considered a causative factor in intensive care unit (ICU) psychosis. Accordingly, the method may alleviate the severity or development of ICU psychosis.
[00013] In some embodiments, the method is applied to acute patients, who are expected to be weaned from the respiratory support system. In other embodiments, the patient has been previously supported by a positive pressure mechanical ventilator (PPMV), or by a combination of electrical diaphragm stimulation, per the presently described invention, and a PPMV. The method includes the support of these patients by the above described system, after the PPMV support has been discontinued.
[00014] As provided by embodiments of the invention, the electrodes may be implanted in the diaphragm any of several anatomical approaches and surgical methods. In some embodiments, the electrodes are implanted by insertion through the abdominal cavity, using either laparoscopic techniques or open surgical techniques. In some embodiments, the electrodes are implanted by insertion through the thoracic cavity, using either thoracoscopic techniques or open surgical techniques. In still other embodiments the electrodes are implanted in the diaphragm by way of insertion through natural orifices, using translumenal endoscopic techniques.
[00015] Ih some embodiments of the invention, the system for the method may further include a positive pressure mechanical ventilator (PPMV), the method further comprising ventilating the patient with the PPMV. In some embodiments, the external stimulator and the PPMV are configured such that the external stimulator controls the PPMV, the method further comprising controlling the PPMV. In such embodiments, controlling the PPMV includes controlling operational parameters of PPMV, the parameters including any of breath rate, gas volume delivered per breath, or airway pressure behind delivered gas. In other embodiments, the external stimulator and the PPMV are configured such that the PPMV controls the external stimulator, the method further comprising controlling the external stimulator. In such embodiments, controlling the external stimulator includes triggering stimulator output at a time in relationship to the PPMV reaching peak pressure. Generally in embodiments that include a PPMV, the method may include controlling the PPMV with a constraint of a maximal tidal volume, or it may include controlling the PPMV with a constraint of a maximal airway pressure
[000161 Ia comparing the maximal airway pressure required to deliver a given tidal volume to a patient with a PPMV with and without diaphragmatic stimulation per embodiments of this invention, the airway pressure required by the PPMV is decreased by the concurrent diaphragmatic stimulation. High airway pressure from a PPMV is associated with barotrauma to the lungs of such treated patients, accordingly, inclusion of diaphragm stimulation may reduce the risk of PPMV-associated barotrauma.
[00017J Embodiments of the invention also include a method for treating a patient with an atelectatic lung region with a system including an external stimulator and one or more electrodes implanted at one or more sites in the diaphragm, the external stimulator configured to stimulate the one or more electrodes independently, and a positive pressure mechanical ventilator (PPMV). The method includes initiating a breath, ventilating the patient with the PPMV during the breath, stimulating the diaphragm with the one or more electrodes during the breath to increase tidal volume and/or to decrease maximal lung pressure during the breath. The electrodes have been implanted or a stimulated such that they preferentially stimulate a specific portion of the diaphragm such that the volume of atelectatic region is expanded, thereby clearing the atelectatic region.
[00018] Embodiments of the invention also include an electrode suitable for temporary placement in tissue that includes a needle at a first end, a central portion including a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a second end including a deinsulated barb and a stop. In some embodiments, the the stop comprises soft silicone. In other embodiments, the stop includes an absorbable suture material thermally bonded to the deinsulated coiled portion. In some embodiments, the needle is a break-away needle. Li some embodiments the straight insulated lead and the helically wound insulated lead are joined at a junction, and the electrode further includes a bonding material disposed at the junction to form a bond configured to prevent the helically wound lead from unwinding.
[00019] Embodiments of the invention further include a method of inserting an electrode suitable for temporary placement in a tissue site, the electrode including a needle at a first end, a central portion comprising a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a deinsulated barb and a stop at a second end. The method includes inserting the electrode into a tissue site surface by the first end comprising the needle, and pulling the electrode through the tissue until the second end comprising the stop is at the tissue site surface. BRIEF DESCRIPTION OF THE DRAWINGS
[00020] Figure 1 is a block diagram of the external stimulator. [00021] Figure 2 shows an example of an implantable electrode.
[00022] Figure 3 is a diagram illustrating a respiratory support system (system 1 ) including an external stimulator.
[00023] Figure 4 is a diagram illustrating a respiratory support system (system 2) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, but without a direct operable connection between the PPMV and the external stimulator.
[00024] Figure 5 is a diagram illustrating a respiratory support system (system 3) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, and with an operable connection between the PPMV and the external stimulator.
[00025] Figure 6 is a block diagram showing three variations of respiratory support methods: (A) support with combination of PPMV and stimulator, with the stimulator initiating air flow into the lungs, (B) support with combination of PPMV and stimulator, with air flow being initiated by the PPMV, and (C) support by the stimulator alone, breath initiation either by the stimulator or by the patient, in which case the stimulator assists in completion of the breath.
[00026] Figure 7 is a diagram illustrating an example of coordinated timing of respiratory support as provided by a combination of an external stimulator and a positive pressure mechanical stimulator.
[00027] Figure 8 is a schematic graph that compares the relationship between internal lung pressure and lung volume over the course a breathing cycle, including an inhalation and an exhalation, in a patient supported by (A) positive pressure delivered by a positive pressure mechanical ventilator (PPMV) alone, and (B) the combination of negative pressure delivered by electrically stimulated diaphragm contraction and positive pressure delivered by a PPMV.
[00028] Figure 9 shows a compliance pattern when respiration is supported by ventilation with a PPMV alone, without diaphragm stimulation.
[00029] Figure 10 shows a compliance pattern when respiration is supported by diaphragm stimulation alone (without PPMV ventilation).
[00030] Figure 11 shows a compliance pattern where diaphragm stimulation initiates a breath that is later supported by PPMV ventilation.
[00031] Figure 12 shows a compliance pattern where a breath is initiated by the PPMV, and is later supported by diaphragm stimulation. [00032] Figures 13A — 13D provides views of airway pressure waveforms on positive pressure mechanical ventilator monitor under various conditions: Figure 9A shows normal airway pressure waveform with ventilator only. Figure 9B shows airway pressure with diaphragm stimulation starting approx. 1 sec into inspiration demonstrating ability to increase tidal volume and modulate airway pressure. Figure 9C shows airway pressure with diaphragm stimulation started near beginning of inspiration and lasting for approx. 1 sec - demonstrating an ability to reduce airway pressure and maintain tidal volume. Figure 78 shows airway pressure with stimulation in first inspiration and no stimulation in second inspiration.
[00033] Figure 10 shows airway compliance shift measured on positive pressure mechanical ventilator.
DETAILED DESCRIPTION OF THE INVENTION
System components
[00034] Components of the system for providing respiratory support by the methods described herein include an external stimulator for electrically stimulating a portion of the diaphragm of a patient, electrodes suitable for implanting in the diaphragm, and a positive pressure mechanical ventilator (PPMV). In some embodiments, the system includes only the stimulator and electrodes for respiratory support; other embodiments include the PPMV as well.
External electrical stimulator and implanted electrodes
[00035] In one embodiment, the electrical signal generator 110 shown in Figure 1 can be configured to generate pulses and/or signals that may take the form of sinusoidal, stepped, trapezoidal waveforms or other relatively continuous signals. The electric signal generator 110 can include one or more channels that can independently control the amplitude, frequency, timing and pulse width of the corresponding electrodes connected thereto.
[00036] In one embodiment, the electrical signal generator 110 can be an external signal generator that is electrically connected to or in electrical communication with the electrodes. One example of a suitable electrical signal generator is the NeuRx RA/4 stimulator that is manufactured by Synapse Biomedical, Inc. of Oberlin, Ohio. The NeuRx RA/4 stimulator is a four-channel device with independent parameter programmability. It will be appreciated that since the NeuRx RA/4 stimulator has four channels, it has the capability to independently control up to four electrodes. In an alternative embodiment, the electrical signal generator 110 can be an implantable signal generator. One suitable example of a fully implanted signal generator is the "Precision" electrical signal generator available from Boston Scientific / Advanced Bionics. One example of a partially implanted radio-frequency signal generator system is the "XTREL" system available from Medtronic, Inc. [00037] The external stimulator 110 depicted in Figure 1 is comprised of several blocks to produce coordinated stimulus output. The core of the device is a supervisory microcontroller 111 that coordinates parameter and sensed inputs, display, and stimulus / trigger outputs. The stimulus and timing parameters are stored in non-volatile memory and are programmed, via a serial interface (not shown), specific to the respiratory support needs and electrode muscle recruitment characteristics of the particular patient. The waveform generator 112 assembles the control signals from the microcontroller in the necessary waveform patterns to be output through the output stage signal drivers 113. The microcontroller 111 receives power from a power supply 114. It receives input of sensing information 115, impedance detection 116, stimulation parameters 117 and timing parameters 118. The microcontroller 111 provides output to a trigger output 119 and an LCD 121, in addition to the waveform generator 112. The output stage comprising drivers 113 also provide output to the impedance detector 116. The drivers 113 provide output in the form of stimulation of the electrodes 120.
[00038] In the preferred embodiment the resultant output is a capacitively coupled, current regulated biphasic waveform. With each stimulus output the circuit impedance is detected and fed back to the microcontroller to display electrode circuit integrity. The microcontroller may be driven to send the control signals to the waveform generator from an external sensed source (either a digital level or analog signal, such as diaphragm EMG) or from internal timing that is based on the stored timing parameters. The microcontroller may also be programmed to send out an analog or digital trigger signal to an external device based on a programmed sequence or event.
[00039] In one example, the electrical signal generator can supply the implantable electrodes with an electrical signal that serves as electrical stimulation to the respiratory system of the patient. For example, the electrical signal can be a capacitively-coupled, charge balanced, biphasic, constant current waveform with adjustable parameters as shown below in Table 1. It will be appreciated that the electrical signal can take the form of other waveforms for electrical stimulation such as monophasic or rectangular biphasic.
Table 1
Figure imgf000009_0001
[000401 Although the stimulatory signal can be delivered to a variety of locations in the body of a patient to stimulate the respiratory system, in one example, the electrical stimulatory can be delivered to the diaphragm of the patient, through the electrodes, continuously or periodically. For example, the electrical stimulation can be delivered to the diaphragm of the patient at specified intervals per day (e.g. 5-6 sessions per day) for a certain period of time per interval (e.g. 5 minutes per session totaling about 25-30 minutes per day). It will be appreciated that the electrical stimulation can be delivered at different intervals depending on the needs of a particular patient.
[00041] The external electrical stimulator makes use of one or more intramuscular electrodes that are suitable for implanting into muscle tissue. In some embodiments, the intramuscular electrode can serve as a cathode. In some embodiments, the electrode is particularly adapted for temporary implantation. Features of implantation that provide long term stability, as in a more permanent placement, tend to work against suitability for short-term placement. It is desirable for an electrode to be able to stably remain in the muscle tissue without migrating from the target implant site, and thus supplemental anchoring is generally helpful. However, for an electrode to be appropriate for temporary placement, it needs to be able to be withdrawn intact without significant trauma to the muscle when no longer needed, and supplemental anchoring tends to complicate withdrawal. Similarly, tissue ingrowth, as encouraged by the anchoring or by features of the electrode is desirable for stabilization and protecting the entry site, but such ingrowth can complicate removal. In some instances the electrode may be treated as temporary by just abandoning its use, however that is unsatisfactory as presents risks to the patient of potential migration of unsecured portions, imaging artifact, or thermal/electrochemical effects if exposed to inappropriate MRI or diathermy.
[00042] One example of a suitable long-term intramuscular electrode is the Peterson intramuscular electrode (P/N 21-0002) manufactured by Synapse Biomedical, Inc. of Oberlin, Ohio. In one configuration, the Peterson intramuscular electrode is a double helix wound from multistrand stainless steel wire insulated in fluoropolymer with a polypropylene core and barb. The electrode can have a barb that is flattened and bent back along the line of the electrode, a polypropylene skirt, and a deinsulated coil under the skirt. The electrode lead can terminate with a stainless steel pin crimped to the de-insulated end and back-filled with silicone adhesive for strain relief. It will be appreciated that the intramuscular electrode can take the form of other shapes, sizes, and configurations, and can be made of other materials suitable for implantation into a patient.
[00043] Another example of an electrode suitable for short-term implantation is shown in Figure 2. This electrode 900 includes five primary elements: a deinsulated stimulating segment 902, a stop 904, a length of helically coiled insulated lead 906, a length of straight insulated lead 908, and a needle 910. The stop may comprise a soft silicone plug. The electrode is inserted, needle end first, into a target site, such as diaphramatic muscle, and pulled through until the stop at the opposite end is reached. Insertion in this manner results in the deinsulated stimulating segment ending up at the surface of the target muscle at the needle entry point. The insulated lead is guided or tunneled to an appropriate exit site and the needle brought through the skin until the insulated coiled lead protrudes from the skin. The junction of the coiled to straight segment of insulated wire is secured with silicone adhesive or other suitable material to maintain the coiled configuration as it is drawn through the muscle tissue and skin interface. The coiled lead allows for tissue ingrowth at the skin exit site, thereby reducing the potential for infection entering and tracking along the lead. The needle may be a breakaway type of needle that can be used to terminate the electrode into the appropriate connector or the straight length of lead may be cut, deinsulated, and terminated into an appropriate connector. The stop maybe a small amount of silicon adhesive or a piece of absorbable suture thermally locked on to the deinsulated lead.
[00044] Another example of a suitable short term intramuscular electrode was disclosed in a U.S. Provisional Patent Application filed on Feb 5, 2007 by Ignagni, Enders, Gelbke, and Crish, entitled "Intramuscular Electrode". In one embodiment of this intramuscular electrode it comprises a single helix multistrand wire stainless steel wire insulated in fluoropolymer with a polypropylene core and barb. Embodiments of this electrode either do not have the additional skirt of the Peterson electrode, or have a skirt of a lighter gauge polypropylene skirt than that of the Peterson intramuscular electrode, so that the electrode maybe withdrawn without the complication of significant ingrowth of tissue around the skirt. The lead can be implanted under video guidance or direct visualization, using the attached needle to thread it into the diaphragm. The needle and lead-in polypropylene core would be cut off after implantation. To withdraw the electrode after the intervention is completed, the electrode would be withdrawn from the opposite end by straightening the helically wound wire and pulling on the polypropylene core and wire simultaneously. This would allow for the electrode to slide out from the tissue with minimal trauma and the polypropylene core would provide the mechanical support to prevent breakage of the wire in the body.
[00045] In one embodiment, the electrodes can be implanted into target sites in the diaphragm of the patient. For example, the electrodes can be implanted into or adjacent the phrenic nerve motor points of the diaphragm (i.e., where the phrenic nerve enters the diaphragm) of the patient. The phrenic nerve motor points of the diaphragm are locations in the diaphragm mat provide the greatest muscle fiber recruitment in response to an applied stimulation.
Respiratory support system variations and operating modes
[00046] Figure 3 is a diagram illustrating a respiratory support system (System 1) including an external stimulator but without a PPMV. Figure 3 is a diagram illustrating an example system 300 for assisting breathing in a patient, the patient's lungs represented as 330. Generally, the system 300 may include a stimulator 305 and one or more implantable electrodes 310 operably connected to the stimulator 305. The stimulator 305 may be configured to emit a stimulatory signal that is communicated to the implantable electrodes 310 through an operable connection 335. The stimulatory signal may be of a variety of types. Example stimulatory signals may include electrical, magnetic, and other signals.
[00047] Figure 4 is a diagram illustrating a respiratory support system (System 2) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, but without a direct operable connection between the PPMV and the external stimulator. Figure 4 is a diagram illustrating an example system 500 for assisting breathing in a patient. Generally, the system 500 may include a stimulator 505 and one or more implantable electrodes 510 operably connected to the stimulator 505. The system 500 may also include a mechanical ventilator 515. The system 500 may also include an airflow measuring instrument or flow sensor 520.
[00048] Generally, the mechanical ventilator 515 may be configured to cycle a gas into the lungs 525 of a patient. The mechanical ventilator 515 may also be configured to cycle the gas out of the lungs 525 of the patient. In one example, the gas is delivered from the mechanical ventilator 515 to the lungs 525 of the patient through a patient circuit 530. One type of patient circuit 530 may include a set of flexible tubes. Generally, one end of the patient circuit 530 may connect to the mechanical ventilator 515 and one end of the patient circuit 530 may connect to the patient through, for example, an endotracheal tube, a tracheostomy tube, a mask covering the patient's face, and the like.
[00049] The stimulator 505 may be configured to emit a stimulatory signal that is communicated to the implantable electrodes 510 through an operable connection 535. The stimulatory signal may be of a variety of types. Example stimulatory signals may include electrical, magnetic, and other signals.
[00050] An example airflow measuring instrument 520 of flow sensor may interact with the system 500 along the ventilation breathing circuit {e.g. , between the mechanical ventilator 515 and the lungs 525 of the patient). The airflow measuring instrument 520 generally is capable of sensing and/or measuring inspiratory and/or expiratory air flow in the ventilatory breaming circuit or cycle {e.g., measuring air flow in the ventilatory breathing circuit). One type of airflow measuring instrument 520 may be a pneumotachometer.
[00051] The airflow measuring instrument 520 may be capable of emitting a signal or facilitating an associated or separate logic and/or software, for example, of emitting a signal related to the sensed or measured airflow. This signal may be communicated or transmitted, directly or indirectly, to the mechanical ventilator 515. This signal may be communicated, for example, via an operable connection 540 between the airflow measuring instrument 520 and the mechanical ventilator 515. The signal from the airflow measuring instrument 520 may also or alternatively be communicated or transmitted, directly or indirectly, to the stimulator 505. This signal may be communicated, for example, via an operable connection 545 between the airflow measuring instrument 520 and the stimulator 505. The signals may facilitate timing or synchronization of a ventilatory cycle with delivery of a stimulatory signal or of delivery of a stimulatory signal with a ventilatory cycle. The signals may also or alternatively facilitate adjustment or variability in one or both of the ventilatory cycle and stimulatory signal.
[00052] Figure 5 is a diagram illustrating a respiratory support system (System 3) including an external stimulator and a PPMV, with an optional air flow sensor (breathing monitor) from the PPMV operably connected to both the PPMV and the external stimulator, and with an operable connection between the PPMV and the external stimulator. Figure 5 is a diagram illustrating an example system 700 for assisting breathing in a patient. Generally, the system 700 may include a stimulator 705 and one or more implantable electrodes 710 operably connected to the stimulator 705. The stimulator 705 maybe configured to emit a stimulatory signal that is communicated to the implantable electrodes 710 through an operable connection 740. The system 700 may also include a mechanical ventilator 715. The mechanical ventilator 715 may be configured to cycle a gas into and/or out of the lungs 730 of a patient via a patient circuit 735. The system 700 may also include an airflow measuring instrument 720. The airflow measuring instrument 720 may be capable of sensing and/or measuring inspiratory and/or expiratory air flow in the ventilatory breathing circuit. The airflow measuring instrument 720, or an example logic associated with or separate from the airflow measuring instrument 720, may be capable of emitting a signal related to the sensed or measured airflow. This signal may be communicated or transmitted, directly or indirectly, to the mechanical ventilator 715. This signal may be communicated, for example, via an operable connection 745 between the airflow measuring instrument 720 and the mechanical ventilator 715.
[00053] The system 700 may also include a breathing sensor and control circuit 725. The breathing sensor and control circuit 725 can be configured to detect and/or determine certain breathing attributes of the patient (e.g., the inspiration phase of a breath, the duration of the inspiration phase, the exhalation phase of a breath, the duration of the exhalation phase, tidal volume, airway pressures, and/or flow rate). These breathing attributes may be communicated to the breathing sensor and control circuit 725 via, for example, an operable connection 750 between the airflow measuring instrument 720 and the breathing sensor and control circuit 725. The breathing sensor and control circuit 725 may process these signals and transmit them to the stimulator 705, for example, via an operable connection 755 between the breathing sensor and control circuit 725 and the stimulator 705. The system 700 may also include an operable connection 760 between the mechanical ventilator 715 and the breathing sensor and control circuit 725. The operable connection 760 may facilitate, for example, timing of a ventilatory cycle with delivery of a stimulatory signal.
[00054] In another example, the system 700 can include a pressure gauge (not shown) and gas meter (not shown), provided along the ventilator breathing circuit, to measure the pressure and/or gas- related parameters of the patient's breathing. Also, a physiological measurement unit can be connected to the patient to measure certain physiological parameters such as blood pressure, blood values, body temperature, etc. These measurements may be used by the system 700 to adjust or modify parameters of ventilation controlled by the mechanical ventilator 715 and or parameters of the stimulatory signal delivered by the stimulator 705.
[00055] Exemplary methods may be better appreciated with reference to the flow diagram of Figure 6 which shows three variations of respiratory support methods: (6A) support with combination of PPMV and stimulator, with the stimulator initiating air flow into the lungs, (6B) support with combination of PPMV and stimulator, with air flow being initiated by the PPMV, and (6C) support by the stimulator alone, breath initiation either by the stimulator or by the patient, in which case the stimulator assists in completion of the breath. Methods shown in 6 A and 6B thus depict respiration support with the combination of electrical stimulation of diaphragm contraction that is further supported by positive airway pressure from the PPMV. By method 6A, the stimulator initiates the breath, and the PPMV provides supplemental gas under pressure to the patient as needed. In method 6B, the breath is initiated by the PPMV initiating a breath by flowing air into the lungs of the patient. In a variation of this method, the patient may initiate a breath that is detected by a gas flow detector on the PPMV, as which point the PPMV provides gas flow to support continuation of the breath. By either variation of method 6B, however, the breath is not initiated by the external stimulator, but the stimulator does activate after the breath is initiated independently of it, from which point forward the stimulator supports the breath by the diaphragm creating negative pressure within the chest. And further, by virtue of the electrode stimulation being to a specific portion of the diaphragm, the gas flow, also being supported by the PPMV is directed to a specific portion of the lung. In method 6C, the respiration is supported by the electrical stimulation of the electrodes, without participation of the PPMV. In embodiment 6C, the breath is typically initiated by the patient volitionally, and the diaphragm stimulation directs the breath by stimulating a specific portion of the diaphragm, which directs airflow toward a specific portion of the lung. In a variation of method 6C, the stimulator may initiate the breath, and then further support it as described.
Respiratory support by electrical stimulation of the diaphragm
[00056] This invention generally relates to manipulating respiratory compliance in patients in need of respiratory support, manipulating compliance in specific portions of the lung, and manipulating compliance toward specific therapeutic benefits. Compliance is manipulated or modulated through the coordinated activity of two therapeutic approaches. A first approach is by electrical stimulation of the diaphragm (diaphragm pacing), which supports respiration by way of generating negative intrathoracic pressure that expands lung volume by an external pull. Embodiments of the invention actually include therapy by this approach alone; other embodiments simultaneously include the second approach as well. The second approach is by way of a positive pressure mechanical ventilator, which supports respiration by generating a positive pressure within the lungs that expands lung volume with an outward push.
[00057] The positive pressure approach to respiratory support is quite powerful, as the mechanical ventilator can easily provide sufficient pressure to expand lung volume. This approach by itself, however has some limitation. The first limitation is that pressure, while effective in expanding lungs, can also damage lung tissue if it is too high, and used for too long a period of time. The second limitation is that positive pressure delivered by a PPMV, by itself, cannot be specifically directed to a portion of a lung. Diaphragm stimulation as a base therapeutic approach provides respiratory support that does not stress lung tissue with high internal pressure, and further, provides a capability to steer volume expansion to particular regions of lung that are in particular need of expansion, such a an atelectatic region. The combining of the two therapeutic approaches not only decreases the need for high airway pressure from the ventilator, but also adds a steering to the moderated internal pressure that the ventilator does provide. In addition to the specific therapeutic benefit of clearing an atelectatic region of a lung, for example, a number of aspects of broader hemodynamic health are provided to the patient by the generally improved respiratory compliance.
[00058] Embodiments of the described invention provide a system and methods to support the respiration of patients in a critical care setting. Such patients are typically in acute need of respiratory support, but they are anticipated to be able to recover from the need for respiratory support. These patients are thus not considered to be in need of chronic support, and accordingly, the electrodes used in this therapeutic method are implanted in the diaphragm in a manner that may be considered temporary. The invention, however, is not limited to acute patients, and may in some instances be appropriate for longer term or chronic management of respiratory disease.
[00059] The system includes an external electrical stimulator and one or more electrodes adapted to be temporarily placed in the diaphragm of a patient, the electrodes being connected to and under the control of an external stimulator. The external stimulator is configured to be able to stimulate each of the electrodes independently of each other. The method by which respiration is supported by electrical stimulation of the diaphragm includes implanting the one or more electrodes in the diaphragm of the patient, initiating a breath, and stimulating the diaphragm with the one or more electrodes during a breath to increase tidal volume and/or to decrease maximal lung pressure during the breath, thereby improving respiratory compliance. As described further below, the breath may be initiated either by the patient or by the respiratory support system. Also, as described further below, the system may further include a positive pressure mechanical ventilator. Basics of the system and method of respiratory support by diaphragmatic stimulation is provided as a stand alone therapy (Le, in the absence of positive pressure support) is not substantially changed by the inclusion of ancillary positive pressure support, and thus will be described first as a stand alone therapy, to be followed by particulars that come with the inclusion of positive pressure support. [00060] A breath may be understood as a breathing cycle that includes a single inspiration phase followed by a single exhalation. As provided by embodiments of the method, a breath or an attempted breath may be initiated the patient, and the patient-initiated breath is then supported at least in some portion through the cycle by diaphragm stimulation. In other embodiments of the method, the breath is initiated by the diaphragm stimulation, and then further supported at least through a portion of the cycle by further or continued diaphragm stimulation. Such an embodiment is appropriate for patients unable to initiate a breath. In this embodiment, the electrical stimulation of the diaphragm not only supports the breath, but it also determines the breathing rate. Regardless of the source of the breath initiation (patient or system), the system then supports the breath through independent stimulation of electrodes, through variation in various signal parameters as described further below, and through variable timing throughout the breath cycle, whether such stimulation is at the beginning, middle, or end of the cycle, or throughout the cycle.
[00061] Returning to the embodiment in which the breath is initiated by the patient, the initiation is sensed by the system through the electrodes themselves. In this embodiment, breath initiation, whether it would ultimately be successful without respiratory support or not, manifests as electrical activity in the diaphragmatic muscle. Such electrical activity is be captured by electrodes in the form of electromyographic data, which are processed by the microcontroller of the system (Figure 1), and interpreted as a breath initiation attempt.
[00062] The electrodes may be implanted in the diaphragm by any of several anatomical approaches and by various surgical methods and tools. In some embodiments, the electrodes are implanted by insertion through the abdominal cavity, using either laparoscopic techniques or open surgical techniques. In other embodiments, the electrodes are implanted by insertion through the thoracic cavity, using either thoracoscopic techniques or open surgical techniques. In still other embodiments the electrodes are implanted in the diaphragm by way of insertion through natural orifices, using translumenal endoscopic techniques.
[00063] The placement of electrodes may be done under direct visualization (e.g. , open surgical technique) or with video observation through a surgical camera. Location of electrode placement may be assisted with electrical stimulation mapping of the diaphragm to identify the phrenic nerve motor point or specific branches. It may be desirable to identify specific branches so as to recruit the largest anatomical surface area {e.g. anterior or posterior) portions of the diaphragm. Mapping may be done in an open procedure, thoracoscopically, or laparoscopically, or endoscopically (using a transgastric approach). Prior laparoscopic and endoscopic techniques have been described in associated patents filings (U.S. Application No. 60/597440, U.S. Pat. No. 5,472,438, and U.S. Patent Published Application No. 2005/0107860) and are incorporated and enhanced with this invention. While direct visualization of the phrenic nerve may be accomplished with an open thoracic or thoracoscopic approach, it may be desirable, as provided by embodiments of this invention, to verify the placement location with electrical stimulation mapping of the diaphragm.
100064] Electrodes may be implanted in the diaphragm muscle with an electrode delivery instrument; one exemplary instrument is described in U.S. Patent No. 5,797,923. Another method, as provided by embodiments of this invention, include the use of an apparatus to puncture through the skin and provide a channel for introduction of a needle loaded with a barbed intramuscular electrode that may be inserted into the diaphragm under thoracoscopic, laparoscopic, or endoscopic visualization. If implanted during an open procedure the intramuscular electrode maybe sewn into the diaphragm using a special electrode that is incorporated into this invention.
[00065] Embodiments of the method include the targeting to specific portions of the diaphragm to stimulate. Such targeting may be brought about by the selection of the diaphragm sites in which the electrodes are implanted, and it may also include the stimulation of a subset of implanted electrodes that are located in a diaphragm site of interest. A specific portion of the diaphragm may, for example, include the left hemidiphragm or the right hemidiaphragm, or any particular portion of the left or right hemidiaphragm. Stimulation of a particular portion of a diaphragm, the right or left hemidiphragm, for example, has the effect of directing or steering negative pressure to a particular portion of a patient's lungs, such as the right lung or the left lung, respectively. A particular portion of a lung may include the lower or posterior portion of the lung. In some embodiments, a particular portion of a lung may suffer from atelectasis, or collapse. In such embodiments, directing negative pressure to the collapsed portion may cause a decrease in or clearing of atelectasis.
Respiratory support by combination of diaphragm stimulation and positive pressure
[00066] As mentioned above, some embodiments of the method include the use of a system that includes a positive pressure mechanical ventilator (PPMV) supplying positive airway pressure to the lungs in addition to the external stimulator stimulating the diaphragm to supply negative pressure external to the lungs. In these embodiments, the external stimulator generally controls the operation of the mechanical ventilator, as the two components are configured in a master - slave relationship. The positive pressure mechanical ventilator may either be invasive {e.g., endotracheal intubation or tracheostomy) or non-invasive {e.g., mask ventilation). The external stimulator may control the operation of PPMV with regard to any of the breath rate, the gas volume delivered per breath, or the airway pressure behind delivered gas. The PPMV can be set at a back-up rate so that the breathing rate is controlled by the stimulator such that either delivered gas volume or delivered airway pressure is controlled during a breath cycle. The PPMV may be controlled in such a way that maximal tidal volume is a constraint. The PPMV may also be controlled such that maximal airway pressure is a constraint. [00067] The PPMV may be set in assist mode, where it assists within a breath cycle initiated either by the patient or by a diaphragm contraction that is stimulated by electrodes, or, alternatively the PPMV may be directly controlled by the external stimulator so that an inspiration initiated by the external stimulator triggers the PPMV to deliver supplemental gases. Further, with regard to the external stimulator, as described above, the stimulator may be configured to provide stimulation at the beginning, middle, or end of an inspiration cycle or coincidental with the entire cycle. The level of stimulation provided may be modulated during the cycle or remain constant (whether the cycle is initiated by the external stimulator or the PPMV). The stimulation may be delivered to all implanted electrodes simultaneously, to electrodes grouped by hemi-diaphragm, or to individual electrodes to preferentially contract portions of a diaphragm. The timing between stimuli delivered to specific electrodes may be sequenced so that the stimuli are delivered simultaneously, spaced throughout the stimulus cycle, or anywhere in between.
[00068] Various sequences of respiratory support with regard to the interplay of the PPMV and diaphragm stimulation are provided. For some patients in acute respiratory distress, an initial period of respiratory support that includes contributions of both a PPMV and diaphragm stimulation may be appropriate upon admission to an intensive care unit. With recovery of function, or clearing of atelectasis, for example, it may be clinically appropriate to wean the patient from the PPMV, discontinue it, and continue respiratory support with the diaphragm stimulation alone. In other cases, diaphragm stimulation may be a sufficient and appropriate mode of therapy alone, without the PPMV support. In still other cases, the condition of a patient on diaphragm stimulatory support may experience a worsening of condition, and benefit from the inclusion of positive pressure support.
[00069] Figure 7 is a diagram illustrating one example of timing between mechanical ventilation and a stimulatory signal 400. The diagram illustrates initiation of a stimulatory signal 405 with the beginning of inspiration 410 that is provided or assisted by a mechanical ventilator. The diagram also illustrates an increase in the level of the stimulatory signal 415 later in the inspiratory cycle 420. This increased stimulatory signal 415 may facilitate moving gases into the lower lobes of the lungs of the patient, for example.
[00070] The profile of generation or delivery of the stimulatory signal in relation to a ventilatory cycle, one example of which is shown in Figure 7, may be modified for individual patients. These modifications may include, but are not limited to, the magnitude of the stimulation, the timing of the stimulation relative to the ventilatory cycle, and the rate {e.g., ramping) at which the stimulatory signal is changed during the cycle. These modifications maybe implemented or facilitated by, for example, software or logic. [00071] It will also be appreciated that stimulation of the diaphragm of the patient may not be synchronized with breathing or attempts at breathing made by the patient and, thus, can be applied during any portion of a breath or ventilatory cycle.
Respiratory compliance
[00072] Respiratory compliance refers to the relationship between lung volume and air pressure within the lung. Optimal lung function is favored good compliance, Le., by a high degree of responsiveness of a change in lung volume in response to change in pressure, as an increase in volume opens alveolae and creates greater lung surface area for gas exchange. Poor compliance impedes the amount of gas exchanged during a breath, which has a number of deleterious and well known consequences. Compliance involves a quality of lung tissue and resistance of airways that is associated with the state of health and integrity in a general sense, but is also a functional quality that can be manipulated or modulated by diaphragm stimulation.
[00073] Mechanical ventilation clearly provides significant benefits that follow from overcoming resistance of airways, expanding constricted alveolae that are associated with a poorly compliant lung, and generally increasing tidal volume. However, mechanical ventilation also has the potential to create high pressures that can traumatize and damage lung tissue. Patients with collapsed portions of lung, or atelectasis, have poor compliance as a consequence of the collapsed portion not expanding in response to pressure. The coordinated action of mechanical ventilation and electrical stimulation of specific diaphragm sites, as provided by the system and methods of this invention, improves compliance.
[00074] The dynamics of pressure and volume in a lung that is being supported by positive pressure mechanical ventilation (PPMV) alone and by a combination of diaphragm stimulation and PPMV is shown in an idealized schematic version in Figure 8A and 8B. A more detailed set off examples is described below, as depicted in Figures 9 - 12. Figure 8A (support by PPMV only) and 8B (support by diaphragm stimulation plus PPMV) both depict lung volume as a function of air pressure within the lung through a breath cycle of a single inspiration and a single exhalation. Pressure is shown on the X-axis, and is relative to atmospheric pressure, atmospheric pressure representing zero on the X-axis. The volume is shown on the Y-axis, and is shown in terms of the increase in volume over the functional reserve capacity of the lung, ϊ.e., the volume at the low point of a normal exhalation. The maximal volume achieved during a normal inhalation is termed the tidal volume.
[00075] The time course through the breath cycle is indicated by arrows. The graphs show the maximal volume achieved in both breaths to reach the same value. It can be seen that the breath supported by positive pressure alone (figure 8A) shows the intralung air pressure to increase steadily from the point of initiation of the inspiration to its conclusion, at the upper right point where the inhalation concludes. Following a different trajectory, shifted to the left, the ratio of volume to pressure falls as a smooth function back to the origin. In contrast, the time course of the volume/pressure ratio of a lung during a breath that is supported by both PPMV and diaphragm- stimulated intrathoracic negative pressure may begin with an immediate drop in pressure if the driving force from the diaphragm stimulation either precedes or is greater than the positive pressure from the PPMV. This pressure drop is due to the stimulated contraction of the diaphragm. At the same time, however, air may be flowing into the lung from the PPMV, and at a certain point that PPMV driving force from the PPMV becomes greater than that of the diaphragm stimulation the pressure reverses while the inflow of air continues. As the pressure begins to rise, the pressure crosses the baseline level, and climbs to the same peak level depicted in figure 8B. The pressure may drop from the peak pressure and be held at a plateau to sustain the given volume. As the pressure falls below the elastic force of the lungs and chest the volume falls steadily back to the origin during exhalation. The specific form of the curve depicted in figure 8B varies with timing of the stimulation, and according to other stimulatory parameters, but the point of this depiction is that under conditions of figure 8B, the lung is more compliant, and for a given maximal volume, the lung tissue is exposed to a significantly lower pressure.
Ϊ00076] Lung compliance may be improved, for example, by modifying diaphragm stimulation parameters to elicit a higher change in tidal volume with each inspiration or by maintaining tidal volume while reducing the delivered pressures. Compliance may be modified, preferentially, on the right or left lobes of the lungs, by separately controlling stimulation levels to the right or left hemi- diaphragm to pull gas to an otherwise unventilated region. This preferential directing of internal gas movement by way of controlling negative intrathoracic pressure can be used to reduce or clear an atelectic region. Contraction of the diaphragm also preferentially pulls the gas to the posterior or dependent lobes of the lungs and helps to prevent pneumonias.
[00077] The addition of negative pressure during the inspiration cycle may also be used to reduce the intra-thoracic pressure and thereby improve the venous return. This has the effect of increasing the cardiac stroke volume and cardiac output, thus improving the patient's hemodynamics. This should also improve any third-spacing that may be a result of PPMV. To optimize hemodynamic improvement outcome the external stimulator may be triggered by the cardiac cycle to provide optimal timing between the left ventricular filling and the contraction of the diaphragm.
[00078] Application of the method, beyond broadly improving respiratory compliance, may consequently improve a number of specific aspects of lung performance and patient health. The method may, for example, improve any of hemodynamics venous return, cardiac output, alveolar ventilation, type 1 muscle fiber condition. The method may decrease any of atlectasis, third spacing, time required for weaning from the PPMV, length of hospital stay, occurrence of pneumonia. The method may condition Type I muscle fibers, and may stimulate the conversion of Type lib muscle fibers into Type I muscle fibers.
[00079] Some patients are at risk for the development of central hypoventilation syndrome (CHS), in such patients, the method may support a regular breathing rate during instances of hypopnea or apneas, particularly during sleep. Disturbed sleep can decrease or prevent occurrence of REM sleep, accordingly, uninterrupted sleep as supported by a regular breathing rate may increase the occurrence or duration of REM sleep. Loss of REM sleep is considered to be a causative or risk factor for intensive care unit (ICU) psychosis. Accordingly, the method may alleviate the severity or development of ICU psychosis.
[00080] What follows now (Figures 9 — 12) is a series of specific comparisons of compliance patterns that manifest under various respiratory support regimens as provided by diaphragm stimulation or PPMV support, alone and in combination. In each example an upper graph A shows a time sequence of activity of both the ventilator (above, if present) and the external electrical stimulation (below, if present), and a lower graph B shows the same data displayed as an graph of volume as a function of pressure. These examples include a pattern (Figure 9) conventional ventilator compliance pattern without diaphragm stimulation, a compliance pattern (Figure 10) with diaphragm stimulation only, a compliance pattern (Figure 11) the breath is initiated by stimulation and is further supported by the PPMV5 and a compliance pattern (Figure 12) where the PPMV initiates the breath and diaphragm stimulation further supports the breath.
[00081] Figure 9 shows a compliance pattern when respiration is supported by ventilation with a PPMV alone, without diaphragm stimulation. As the ventilator pressure/flow starts to increase during inspiration (701) the volume build slowly increases (702). At a given point (703) the airflow resistance decreases and the rate of volume to pressure increase becomes greater until the peak pressure (704) is reached. Once the desired volume is attained the plateau pressure is maintained (705) and the volume is held (706). Upon expiration (707), the volume is maintained (706) until the pressure falls below the elastic force of the respiratory system and an exhalation occurs (708).
[00082] Figure 10 shows a compliance pattern when respiration is supported by diaphragm stimulation alone (without PPMV ventilation). The stimulation is initiated (711) causing a negative pressure increase with volume drawn into the lungs (712). Once the peak stimulation level (714) is reached the peak pressure (713) is obtained and the volume held (715). Once the stimulation is turned off or ramped down (716) the inspired volume will be exhaled (717).
[00083] Figure 11 shows a compliance pattern where diaphragm stimulation initiates a breath that is later supported by PPMV ventilation. The stimulation initiates the breath (721) causing a negative pressure with increasing volume (722). If the ventilator pressure exceeds the negative pressure force from the stimulation (723) the pressure curve will become positive with increasing volume (724). If the ventilator pressure is less than the negative pressure force from the stimulation (723) the pressure curve will remain negative with increasing volume (not shown). After the plateau pressure and maximum volume (725) is reached the exhalation phase may commence. The pressure is decreased until the elastic recoil of the lungs and chest causes exhalation (727). The pressure may become negative again depending on the relative force from the stimulation to the PPMV (726).
[00084] Figure 12 shows a compliance pattern where a breath is initiated by the PPMV, and is later supported by diaphragm stimulation. The PPMV initiates the breath (731) causing a positive pressure with increasing volume (732). If the ventilator pressure is less than the negative pressure force from the stimulation (733) the pressure curve will become negative with increasing volume (734). If the ventilator pressure exceeds the negative pressure force from the stimulation (733) the pressure curve will remain positive with increasing volume (not shown). After the plateau pressure and maximum volume (735) is reached the exhalation phase may commence. The pressure is decreased until the elastic recoil of the lungs and chest causes exhalation (737). The pressure may become positive again depending on the relative force from the stimulation to the PPMV (736).
Examples of Applying the Invention
Example 1. Interaction of respiratory support by positive pressure ventilation and negative intrathoracic pressure by diaphragm stimulation
[00085] Figures 13A - 9I> show screenshots of patient data collected from a study in which positive pressure ventilation and diaphragm stimulation were variously applied. Fig 13A (bottom left) shows a normal airway pressure waveform with ventilator support only, without diaphragm stimulation. These data show the typical increase in airway pressure until the desired tidal volume (Vτ = 0.52 liters) is achieved. A peak airway pressure (PPEAK) of 17 cm H2O and mean airway pressure (PM) of 5 cm H2O is reached under the ventilator only conditions. The minute ventilation of 4.2 liters/minute is displayed for the given VT and the measured respiratory rate (RR = 8 breaths per minute) with is calculated as MV = VT * RR.
[00086] Figure 9B (bottom right) shows airway pressure with diaphragm stimulation starting approximately 1 sec into inspiration, thus demonstrating ability to increase tidal volume and modulate airway pressure. In a "failure to oxygenate" patient the airway pressures and tidal volumes would be specifically controlled to recruit collapsed lung units (e.g. decrease atelectasis). These data demonstrate the ability to increase Vτ (= 0.62 liters) while decreasing the airway pressures (PPEAK = 13, PM = 2) as compared to the ventilatory only readings. Normally, a clinician would increase the airway pressures and tidal volume to recruit collapsed lung units. By adding in the diaphragm stimulation at appropriate time during the ventilatory cycle, the peak airway pressure needed to overcome any large airway resistances may be applied and the plateau pressure (PPLAT) reduced or eliminated thus avoiding overdistension of the lungs. In the displayed data, a stimulation pulse of 25mA / lOOμs was used to recruit diaphragm muscle contraction at a maximal level.
[00087] Figure 13C (top left) shows airway pressure with diaphragm stimulation started near the beginning of inspiration and lasting for approximately. 1 sec, thus demonstrating ability to reduce airway pressure and maintain tidal volume. For these data, a lower level of stimulation was used, 10mA / lOOμs pulse, to reduce airway pressures (PPEAK = 12 cm H2O, PM = 3 cm H2O) while maintaining a constant tidal volume (Vτ = 0.52 liters).
[00088] Figure 13D (top right) shows airway pressure with stimulation in first inspiration and no stimulation in second inspiration. These data demonstrate the ability to modulate the airway pressure on a breath by breath basis.
[00089] Figure 14 demonstrates the addition of synchronous breaths to a volume ventilator and the effect upon respiratory system compliance (CRS). The nominal settings, without diaphragm stimulation, provided PPEAK = 14 cm H2O, PPLAT = 12 cm H2O, CRS = 67 ml / cm H2O, and Vτ = 720ml. The addition of diaphragm stimulation early in the inspiratory cycle caused the pressure to initiate negative with increasing volume and then proceed with the continued delivery of the ventilator volume positive prior to returning to zero with completion of expiration, as shown in the pressure- volume curve in the upper left portion of the figure. The resultant tidal volume was the "stacked" volumes from the diaphragm and the ventilator, Vτ = 1,580ml. Because of the high volume delivered the pressures increased (PPEAK =25cm H2O, PPLA=23cm H2O). The respiratory system compliance also increased with the corresponding increase in volume and pressure (CRS = 73 ml / cm H2O).
Example 2. Application of diaphragm pacing to treatment of ALS patients
[00090] Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease) is a condition leading to fatal motor neuron degeneration. Muscular weakness typically progresses at the rate of 1.8% to 3.5% per month. When the muscle deterioration reaches the diaphragm, the patient develops hypercarbic respiratory failure, leading to death. ALS patients may experience different rates of decline in their left and right hemidiaphragms.
[00091] A mechanical ventilator (also known as positive pressure mechanical ventilator or PPMV) can be used to maintain breathing in ALS patients in an invasive (with tracheostomy) or non-invasive (with mask or nasal cannula) manner, but there are certain negative aspects to mechanical ventilation. In addition to the significant costs of ventilators, ventilated patients suffer from speech difficulty, further reduced mobility, and create a heightened burden on caregivers. More significant are the deleterious physiologic effects of positive pressure ventilation, such as a decrease in remaining diaphragm strength due to atrophy of the muscle and to conversion of Type I fibers to Type lib. The increased thoracic pressure caused by PPMV can lead to decreased cardiac output and barotrauma, with possible posterior lobe collapse, atelectasis and/or pneumonia. Further, many ALS patients do not tolerate non-invasive PPMV, due to the bulbar symptoms of the disease, and most of them do not accept invasive PPMV.
[00092] Functional electrical stimulation of the diaphragm, with or without PPMV, can pace the diaphragm to maintain diaphragm function. In addition to assisting breathing by causing diaphragm contraction through direct stimulation at phrenic nerve motor points, diaphragm pacing can induce new nerve branching in the diaphragm, counteract muscle atrophy and slow the decline of forced vital capacity (FVC) in ALS patients. Diaphragm pacing can reduce patient airway pressure, increase overall ventilation, increase diaphragm strength, maintain Type 1 diaphragm muscle fibers, improve cardiac output and provide increased posterior lobe ventilation.
[00093] Twelve patients with FVC between 50 - 80% and >45% at the time of surgery (average 58% FVC) were enrolled in the study. Electrodes were implanted laparoscopically in the patients' two hemidiaphragms at motor points determined during an earlier mapping procedure, and stimulation was provided in 30 minute sessions three to five times per day. Stimulation was provided at 12 Hz, with the pulse width and amplitude as much as the patient could tolerate (typically around 10 ma, pulse width 150 ms) to provide the patient with 8 — 15 breaths per minute. Patients were permitted to increase stimulation utilization over time if desired. In addition to measuring FVC and other lung capacity parameters, diaphragm thickness was measured ultrasonically, blood gases were sampled, and patient quality of life information was surveyed.
[00094] The diaphragm pacing system used for stimulation can provide different stimulation signals to each electrode in each hemidiaphragm. Stimulation parameters can be varied by amplitude, frequency, rate, pulse width and pulse modulation. Diaphragm muscle mass increased over the course of the diaphragm pacing as shown in the Table 2 below:
Table 2
Figure imgf000024_0001
[00095] In addition, improved diaphragm movement was observed under fluoroscopy. Diaphragm contraction increased with stimulation compared to volitional movement an average of 1.5 cm per hemidiaphragm. Furthermore, the decline of FVC decreased from 2.8% to 1.0%, thereby delaying the time when the ALS patient would need to begin using mechanical ventilation.
[00096] The diaphragm stimulation in ALS patients was also shown to sustain the respiratory function of the patients as measured by standard means using the revised ALS Functional Rating Scale (ALSFRSr). In the set of patients studied the overall functional rating score decreased at a rate of 0.7 points per month while the respiratory subscore remained constant. These same patients showed a decline in physical and emotional domains of a standard quality of life instrument, the SF- 36 prior to treatment and demonstrated an improving trend in scores post treatment.
[00097] Diaphragm pacing can also be used together with non-invasive mechanical ventilation in the ALS patients to decrease peak airway pressure and increase tidal volume, making the intervention of non-invasive PPMV tolerated by a greater portion of ALS patients. This intervention would also increase respiratory compliance, reduce atelectatic lung regions and thereby reduce the risks of acute respiratory failures.
Example 3. Respiratory support for a heavily sedated ICU patient
[00098] For a heavily sedated ICU patient with no respiratory drive a volume ventilator mode may be used to provide ventilatory needs. The diaphragm pacing may be used to assist in this case to (1) preferentially ventilate the dependent portions of the lungs to avoid atelectasis, (2) reduce the applied pressures, and (3) reduce the work of breathing by increasing the respiratory system compliance, as outlined below.
1. To preferentially ventilate the dependent portions of the lungs the stimulation may be applied after the volume delivery commences (after the peak pressure but prior to completion of the positive gas flow) to draw the delivered air to the posterior lobes. With a heavily sedated patient higher stimulus parameters may be used, if needed, as any discomfort from the stimulus would not be felt by the patient.
2. To reduce the applied pressures the stimulation may initiate coincidental to the ventilated breath to reduce peak airway pressure or subsequent to the peak to reduce the plateau pressure. The stimulation could be ramped on at a rate (over the gas delivery) to avoid an inrush of negative inspiratory force and stacked breaths.
3. The stimulation may be applied at a lower level (e.g. amplitude of 10mA as opposed to 25mA) at the beginning of the ventilatory cycle to reduce initial peak pressures or throughout the gas delivery to reduce peak and plateau pressure while maintaining the tidal volume (as in figure 3C) thus increasing the respiratory system compliance.
[00099] For a patient that is not heavily sedated and/or is appropriate for pressure support ventilation the stimulation can be used to provide the primary ventilatory support with the ventilator as a backup. The diaphragm stimulation would be set to obtain the desired volume at stimulation values mat the patient could tolerate. For a typical patient the stimulus may be set in a range of 10 - 25mA at a pulse duration of lOOμs and pulse frequency of 10 — 15ELz. If adequate ventilation is obtained the ventilator would be set to provide only backup to the stimulated support. If adequate volumes are not obtained the ventilator pressure would be increased until adequate volumes are obtained. This support could be done with endotracheal or mask ventilation. [000100] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, or patent application were specifically and individually indicated to be so incorporated by reference.
[0001011 Other variations of method and aspects of the system can be employed to achieve the objectives of the invention without departing from the scope of the invention, as will be appreciated by those skilled in the art. While various embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. The invention generally relates to manipulating respiratory compliance toward therapeutic ends, and in describing the invention, the application has offered some theoretical explanation as to how these ends may be achieved. It should be understood, however, that such theories and interpretation do not bind or limit the claims with regard to the therapeutic benefits brought about by the practice of the invention. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. It should be thusly and further understood that various alternatives to the embodiments of the invention described herein that may be employed in practicing the present invention are considered equivalents to the invention, and that it is intended that the scope of the invention includes such equivalents.

Claims

CLAIMSWe claim:
1. An electrode suitable for temporary placement in tissue comprising: a needle at a first end, a central portion comprising a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a deinsulated barb and a stop at a second end.
2. The electrode of claim 1 wherein the stop comprises soft silicone.
3. The electrode of claim 1 wherein the stop comprises an absorbable suture material thermally bonded to the deinsulated coiled portion.
4. The electrode of claim 1 wherein the needle is a break-away needle.
5. The electrode of claim 1 wherein the straight insulated lead and the helically wound insulated lead are joined at a junction, the electrode further comprising a bonding material disposed at the junction to form a bond configured to prevent the helically wound lead from unwinding.
6. A method of inserting an electrode suitable for temporary placement in a tissue site, the electrode comprising a needle at a first end, a central portion comprising a straight insulated lead, a helically wound insulated lead portion, and a deinsulated coiled portion, and a deinsulated barb and a stop at a second end, the method comprising inserting the electrode into a tissue site surface by the first end comprising the needle, and pulling the electrode through the tissue until the second end comprising the stop is at the tissue site surface.
7. The method of claim 6 wherein the electrode stop comprises soft silicone.
8. The method of claim 6 wherein the electrode stop comprises an absorbable suture material thermally bonded to the deinsulated coiled portion.
9. The method of claim 6 wherein the electrode needle is a break-away needle.
10. The method of claim 6 wherein the electrode's straight insulated lead and the helically wound insulated lead are joined at a junction, the electrode further comprising a bonding material disposed at the junction to form a bond configured to prevent the helically wound lead from unwinding.
PCT/US2007/006135 2006-03-09 2007-03-09 Ventilator assist system and method to improve respiratory function WO2007103585A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07752811A EP1996284A2 (en) 2006-03-09 2007-03-09 Ventilatory assist system and method to improve respiratory function

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US76720106P 2006-03-09 2006-03-09
US60/767,201 2006-03-09
US86156806P 2006-11-28 2006-11-28
US60/861,568 2006-11-28
US87226506P 2006-12-01 2006-12-01
US60/872,265 2006-12-01

Publications (2)

Publication Number Publication Date
WO2007103585A2 true WO2007103585A2 (en) 2007-09-13
WO2007103585A3 WO2007103585A3 (en) 2008-01-03

Family

ID=38475618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006135 WO2007103585A2 (en) 2006-03-09 2007-03-09 Ventilator assist system and method to improve respiratory function

Country Status (3)

Country Link
US (2) US7962215B2 (en)
EP (1) EP1996284A2 (en)
WO (1) WO2007103585A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059033A1 (en) * 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
US9079016B2 (en) 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
US9820671B2 (en) 2007-05-17 2017-11-21 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009291A2 (en) * 2003-07-23 2005-02-03 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US20070044669A1 (en) * 2005-08-24 2007-03-01 Geise Gregory D Aluminum can compacting mechanism with improved actuation handle assembly
US20070150023A1 (en) * 2005-12-02 2007-06-28 Ignagni Anthony R Transvisceral neurostimulation mapping device and method
US8571662B2 (en) 2007-01-29 2013-10-29 Simon Fraser University Transvascular nerve stimulation apparatus and methods
EP2170458A1 (en) * 2007-06-13 2010-04-07 E- Pacing, Inc. Implantable devices and methods for stimulation of cardiac or other tissues
US20080312712A1 (en) * 2007-06-13 2008-12-18 E-Pacing, Inc. Implantable Devices and Methods for Stimulation of Cardiac or Other Tissues
US20090188500A1 (en) * 2008-01-29 2009-07-30 Joseph Dee Faram Combination breathing treatment method
US8826907B2 (en) 2008-06-06 2014-09-09 Covidien Lp Systems and methods for determining patient effort and/or respiratory parameters in a ventilation system
CA2736540C (en) 2008-09-25 2015-11-24 Nellcor Puritan Bennett Llc Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators
US8195297B2 (en) 2008-10-13 2012-06-05 E-Pacing, Inc. Devices and methods for electrical stimulation of the diaphragm and nerves
US9055880B2 (en) * 2008-12-18 2015-06-16 Maquet Critical Care Ab Method and apparatus for determining an in vivo position of an esophageal catheter
JP5619913B2 (en) * 2009-12-17 2014-11-05 カーディアック ペースメイカーズ, インコーポレイテッド Electrical suppression of the phrenic nerve during cardiac pacing
US8783250B2 (en) 2011-02-27 2014-07-22 Covidien Lp Methods and systems for transitory ventilation support
US8714154B2 (en) 2011-03-30 2014-05-06 Covidien Lp Systems and methods for automatic adjustment of ventilator settings
US8972027B2 (en) * 2011-07-19 2015-03-03 Shalom MANOVA Implantable medical device including electrode element, anchoring element and elastic element
EP4070850A1 (en) 2012-03-05 2022-10-12 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
AU2013280184B2 (en) 2012-06-21 2017-08-24 Lungpacer Medical Inc. Transvascular diaphragm pacing systems and methods of use
US10362967B2 (en) 2012-07-09 2019-07-30 Covidien Lp Systems and methods for missed breath detection and indication
US20160317765A1 (en) * 2013-11-15 2016-11-03 Mermaid Care A/S Decision support system for lung ventilator settings
EP3760276B1 (en) 2013-11-22 2023-08-30 Lungpacer Medical Inc. Apparatus for assisted breathing by transvascular nerve stimulation
EP3096835B1 (en) 2014-01-21 2019-08-07 Lungpacer Medical Inc. Systems for optimization of multi-electrode nerve pacing
US9808591B2 (en) 2014-08-15 2017-11-07 Covidien Lp Methods and systems for breath delivery synchronization
US9950129B2 (en) 2014-10-27 2018-04-24 Covidien Lp Ventilation triggering using change-point detection
US20160235623A1 (en) * 2015-02-16 2016-08-18 Michael Mirzoyan Invasive Intermittent Negative Pressure Ventilation
US10905836B2 (en) 2015-04-02 2021-02-02 Hill-Rom Services Pte. Ltd. Manifold for respiratory device
JP2018122093A (en) * 2017-02-02 2018-08-09 キヤノンメディカルシステムズ株式会社 Medical image processor, x ray ct device and medical image processing method
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US20190001126A1 (en) 2017-06-30 2019-01-03 Lungpacer Medical Inc. Devices and methods for prevention, moderation, and/or treatment of cognitive injury
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
CN109954205B (en) 2017-12-14 2023-06-27 财团法人工业技术研究院 Electrical stimulation control circuit and control method
EP3793656A1 (en) 2018-05-14 2021-03-24 Covidien LP Systems and methods for respiratory effort detection utilizing signal distortion
US11752287B2 (en) 2018-10-03 2023-09-12 Covidien Lp Systems and methods for automatic cycling or cycling detection
EP3877043A4 (en) 2018-11-08 2022-08-24 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
US11357979B2 (en) 2019-05-16 2022-06-14 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
WO2020252037A1 (en) 2019-06-12 2020-12-17 Lungpacer Medical Inc. Circuitry for medical stimulation systems
US11324954B2 (en) 2019-06-28 2022-05-10 Covidien Lp Achieving smooth breathing by modified bilateral phrenic nerve pacing
JP2023500778A (en) 2019-09-26 2023-01-11 ヴィスカルディア インコーポレイテッド Implantable medical systems, devices, and methods for influencing cardiac function through diaphragmatic stimulation and for monitoring diaphragmatic health

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6397108B1 (en) * 2000-04-03 2002-05-28 Medtronic Inc. Safety adaptor for temporary medical leads
US20050021102A1 (en) * 2003-07-23 2005-01-27 Ignagni Anthony R. System and method for conditioning a diaphragm of a patient

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1693734A (en) 1923-06-29 1928-12-04 Mcintosh Electrical Corp Switching means for effecting electrotherapeutic treatment
US2532788A (en) 1948-01-03 1950-12-05 Stanley J Sarnoff Artificial respiration by electronic stimulation
US2664880A (en) 1951-11-23 1954-01-05 Jr Nathaniel B Wales Electric stimulator for artificial respiration
US6210970B1 (en) 1980-01-14 2001-04-03 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
US6194217B1 (en) 1980-01-14 2001-02-27 Esa, Inc. Method of diagnosing or categorizing disorders from biochemical profiles
US4699875A (en) 1982-11-24 1987-10-13 Baylor College Of Medicine Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors
FR2566276B1 (en) 1984-06-21 1988-07-08 Medtronic Bv DIAPHRAGMATIC STIMULATION METHOD AND APPARATUS
US4827935A (en) * 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US4830008A (en) 1987-04-24 1989-05-16 Meer Jeffrey A Method and system for treatment of sleep apnea
US5368035A (en) * 1988-03-21 1994-11-29 Boston Scientific Corporation Ultrasound imaging guidewire
US4989617A (en) * 1989-07-14 1991-02-05 Case Western Reserve University Intramuscular electrode for neuromuscular stimulation system
US5056519A (en) 1990-05-14 1991-10-15 Vince Dennis J Unilateral diaphragmatic pacer
US5241957A (en) 1991-11-18 1993-09-07 Medtronic, Inc. Bipolar temporary pacing lead and connector and permanent bipolar nerve wire
US7429262B2 (en) * 1992-01-07 2008-09-30 Arthrocare Corporation Apparatus and methods for electrosurgical ablation and resection of target tissue
JPH07507873A (en) 1992-06-12 1995-08-31 ベイラー・カレッジ・オブ・メディシン Diagnostic method and kit for amyotrophic lateral sclerosis
US5843641A (en) 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US5813399A (en) * 1993-03-16 1998-09-29 Puritan Bennett Corporation System and method for closed loop airway pressure control during the inspiratory cycle of a breath in a patient ventilator using the exhalation valve as a microcomputer-controlled relief valve
US5792165A (en) 1993-07-21 1998-08-11 Charles H. Klieman Endoscopic instrument with detachable end effector
US5472438A (en) 1993-07-22 1995-12-05 Case Western Reserve University Laproscopic vacuum delivery apparatus for a diaphragm daper
US5429636A (en) * 1993-10-08 1995-07-04 United States Surgical Corporation Conductive body tissue penetrating device
US5524632A (en) 1994-01-07 1996-06-11 Medtronic, Inc. Method for implanting electromyographic sensing electrodes
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
US5718248A (en) * 1994-04-15 1998-02-17 Allegheny-Singer Research Institute Muscle energy converter pump and method of pumping fluid of a patient
US6405732B1 (en) * 1994-06-24 2002-06-18 Curon Medical, Inc. Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US5678535A (en) * 1995-04-21 1997-10-21 Dimarco; Anthony Fortunato Method and apparatus for electrical stimulation of the respiratory muscles to achieve artificial ventilation in a patient
US5591216A (en) 1995-05-19 1997-01-07 Medtronic, Inc. Method for treatment of sleep apnea by electrical stimulation
US6198970B1 (en) 1995-10-27 2001-03-06 Esd Limited Liability Company Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
US5716392A (en) * 1996-01-05 1998-02-10 Medtronic, Inc. Minimally invasive medical electrical lead
JP3930052B2 (en) 1996-02-15 2007-06-13 バイオセンス・インコーポレイテッド Catheter-based surgery
SE9603841D0 (en) 1996-10-18 1996-10-18 Pacesetter Ab A tissue stimulating apparatus
US6311692B1 (en) 1996-10-22 2001-11-06 Epicor, Inc. Apparatus and method for diagnosis and therapy of electrophysiological disease
US6035856A (en) 1997-03-06 2000-03-14 Scimed Life Systems Percutaneous bypass with branching vessel
US5797923A (en) 1997-05-12 1998-08-25 Aiyar; Harish Electrode delivery instrument
US6477423B1 (en) * 1997-05-28 2002-11-05 Transneuronix, Inc. Medical device for use in laparoscopic surgery
US7006871B1 (en) * 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
AU3458197A (en) * 1997-07-16 1999-02-10 Impulse Dynamics N.V. Smooth muscle controller
US7165551B2 (en) * 1998-02-19 2007-01-23 Curon Medical, Inc. Apparatus to detect and treat aberrant myoelectric activity
US6845271B2 (en) 1998-06-03 2005-01-18 Neurocontrol Corporation Treatment of shoulder dysfunction using a percutaneous intramuscular stimulation system
US6463327B1 (en) 1998-06-11 2002-10-08 Cprx Llc Stimulatory device and methods to electrically stimulate the phrenic nerve
US6213960B1 (en) 1998-06-19 2001-04-10 Revivant Corporation Chest compression device with electro-stimulation
SE9803508D0 (en) 1998-10-14 1998-10-14 Siemens Elema Ab Assisted Breathing System
US6245053B1 (en) 1998-11-09 2001-06-12 Medtronic, Inc. Soft tip guiding catheter and method of fabrication
US6645145B1 (en) * 1998-11-19 2003-11-11 Siemens Medical Solutions Usa, Inc. Diagnostic medical ultrasound systems and transducers utilizing micro-mechanical components
ATE483490T1 (en) * 1999-06-30 2010-10-15 Univ Florida MONITORING SYSTEM FOR FAN
US7177686B1 (en) * 1999-11-10 2007-02-13 Pacesetter, Inc. Using photo-plethysmography to monitor autonomic tone and performing pacing optimization based on monitored autonomic tone
US6689062B1 (en) * 1999-11-23 2004-02-10 Microaccess Medical Systems, Inc. Method and apparatus for transesophageal cardiovascular procedures
US6254425B1 (en) 1999-11-30 2001-07-03 Ethicon, Inc. Electrical connector for cardiac devices
US6415183B1 (en) * 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
WO2001068073A2 (en) 2000-03-14 2001-09-20 Children's Medical Center Corporation, The Method for improving respiratory function and inhibiting muscular degeneration
AU2001249308A1 (en) 2000-03-24 2001-10-15 Johns Hopkins University Peritoneal cavity device and method
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20030148404A1 (en) 2000-07-27 2003-08-07 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
AU2001285170B2 (en) 2000-08-21 2006-10-26 The Brigham And Women's Hospital, Inc. Methods for diagnosing a neurodegenerative condition
JP2004517634A (en) 2000-10-27 2004-06-17 ベイラー カレッジ オブ メディシン Methods and compositions for identification and treatment of neurodegenerative diseases
SE0004141D0 (en) 2000-11-13 2000-11-13 Siemens Elema Ab Method of adaptive triggering of breathing devices and a breathing device
US6754536B2 (en) * 2001-01-31 2004-06-22 Medtronic, Inc Implantable medical device affixed internally within the gastrointestinal tract
FR2822238B1 (en) 2001-03-16 2003-08-29 Gemac METHOD AND KIT FOR MONITORING NEURODEGENERATIVE DISEASES
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US6600956B2 (en) 2001-08-21 2003-07-29 Cyberonics, Inc. Circumneural electrode assembly
US20050171579A1 (en) 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US20060035849A1 (en) * 2002-02-13 2006-02-16 Danafarber Cancer Institute, Inc Methods and composition for modulating type I muscle formation using pgc-1 alpha
US7166075B2 (en) * 2002-03-08 2007-01-23 Wisconsin Alumni Research Foundation Elastographic imaging of in vivo soft tissue
US7463934B2 (en) 2002-04-12 2008-12-09 Medtronic, Inc. Implantable medical device with captivation fixation
US7207946B2 (en) 2002-05-09 2007-04-24 Spiration, Inc. Automated provision of information related to air evacuation from a chest cavity
US7753924B2 (en) 2003-09-04 2010-07-13 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
SE0202537D0 (en) * 2002-08-28 2002-08-28 Siemens Elema Ab Nerve stimulation apparatus
JP4678189B2 (en) * 2002-08-30 2011-04-27 東洋紡績株式会社 Continuous production method of polyamide
US20040064069A1 (en) * 2002-09-30 2004-04-01 Reynolds Brian R. Medical device with support member
US20060041022A1 (en) 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
WO2004052459A1 (en) 2002-12-09 2004-06-24 Medtronic, Inc. Concavity of an implantable medical device
US6945956B2 (en) * 2002-12-23 2005-09-20 Medtronic, Inc. Steerable catheter
US20060160087A1 (en) 2003-01-31 2006-07-20 Mcgrath Michael Monitoring and treatment of amyotrophic lateral sclerosis
US7044921B2 (en) * 2003-02-03 2006-05-16 Scimed Life Systems, Inc Medical device with changeable tip flexibility
US20040167437A1 (en) * 2003-02-26 2004-08-26 Sharrow James S. Articulating intracorporal medical device
US7182735B2 (en) * 2003-02-26 2007-02-27 Scimed Life Systems, Inc. Elongated intracorporal medical device
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20040254419A1 (en) 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US7155278B2 (en) 2003-04-21 2006-12-26 Medtronic, Inc. Neurostimulation to treat effects of sleep apnea
US20040254572A1 (en) 2003-04-25 2004-12-16 Mcintyre Jon T. Self anchoring radio frequency ablation array
GB0309916D0 (en) 2003-04-30 2003-06-04 Ares Trading Sa Secreted protein family
US20060064137A1 (en) 2003-05-16 2006-03-23 Stone Robert T Method and system to control respiration by means of simulated action potential signals
US20060287679A1 (en) 2003-05-16 2006-12-21 Stone Robert T Method and system to control respiration by means of confounding neuro-electrical signals
US20060111755A1 (en) 2003-05-16 2006-05-25 Stone Robert T Method and system to control respiration by means of neuro-electrical coded signals
US7738952B2 (en) * 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US20040260337A1 (en) 2003-06-18 2004-12-23 Scimed Life Systems, Inc. Endoscopic instruments and methods of manufacture
US8469993B2 (en) 2003-06-18 2013-06-25 Boston Scientific Scimed, Inc. Endoscopic instruments
US6918871B2 (en) * 2003-06-19 2005-07-19 Ethicon Endo-Surgery, Inc. Method for accessing cavity
US7824368B2 (en) 2003-06-19 2010-11-02 Ethicon Endo-Surgery, Inc. Method for endoscopic, transgastric access into the abdominal cavity
US8579804B2 (en) 2003-06-23 2013-11-12 Boston Scientific Scimed, Inc. Variable length nephrostomy sheath
WO2005009531A1 (en) 2003-07-23 2005-02-03 University Hospitals Of Cleveland Mapping probe system for neuromuscular electrical stimulation apparatus
US7187982B2 (en) 2003-08-08 2007-03-06 Medtronic, Inc. Medical electrical lead anchoring
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
EP1670547B1 (en) 2003-08-18 2008-11-12 Cardiac Pacemakers, Inc. Patient monitoring system
US7616988B2 (en) 2003-09-18 2009-11-10 Cardiac Pacemakers, Inc. System and method for detecting an involuntary muscle movement disorder
US7641621B2 (en) 2003-08-25 2010-01-05 Boston Scientific Scimed, Inc. Elongated intra-lumenal medical device
US7833175B2 (en) * 2003-09-05 2010-11-16 Boston Scientific Scimed, Inc. Medical device coil
US7540845B2 (en) * 2003-09-05 2009-06-02 Boston Scientific Scimed, Inc Medical device coil
US20050054952A1 (en) 2003-09-05 2005-03-10 Scimed Life Systems, Inc. Elongated medical device for intracorporal use
AU2004278782A1 (en) 2003-10-03 2005-04-14 Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Use of Cripto-1 as a biomarker for neurodegenerative disease and method of inhibiting progression thereof
NO319063B1 (en) * 2003-10-06 2005-06-13 Laerdal Medical As Medical patient simulator
US8244358B2 (en) 2003-10-15 2012-08-14 Rmx, Llc Device and method for treating obstructive sleep apnea
US20060167523A1 (en) * 2003-10-15 2006-07-27 Tehrani Amir J Device and method for improving upper airway functionality
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US9259573B2 (en) * 2003-10-15 2016-02-16 Rmx, Llc Device and method for manipulating exhalation
US7970475B2 (en) 2003-10-15 2011-06-28 Rmx, Llc Device and method for biasing lung volume
US8160711B2 (en) 2003-10-15 2012-04-17 Rmx, Llc Multimode device and method for controlling breathing
US7979128B2 (en) 2003-10-15 2011-07-12 Rmx, Llc Device and method for gradually controlling breathing
US7858071B2 (en) 2003-10-23 2010-12-28 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for amyotrophic lateral sclerosis
EP1682215B1 (en) 2003-10-24 2008-12-24 Cardiac Pacemakers, Inc. Myocardial lead attachment system
EP1684655A2 (en) 2003-11-18 2006-08-02 SciMed Life Systems, Inc. System and method for tissue ablation
US7802571B2 (en) 2003-11-21 2010-09-28 Tehrani Fleur T Method and apparatus for controlling a ventilator
US7237313B2 (en) 2003-12-05 2007-07-03 Boston Scientific Scimed, Inc. Elongated medical device for intracorporal use
US7824345B2 (en) 2003-12-22 2010-11-02 Boston Scientific Scimed, Inc. Medical device with push force limiter
US20050149072A1 (en) 2003-12-31 2005-07-07 Devries Robert B. Devices and methods for tissue invagination
US7519425B2 (en) * 2004-01-26 2009-04-14 Pacesetter, Inc. Tiered therapy for respiratory oscillations characteristic of Cheyne-Stokes respiration
WO2005077268A1 (en) 2004-02-18 2005-08-25 Maquet Critical Care Ab Method and device using myoelectrical activity for optimizing a patient’s ventilatory assist
US20050209653A1 (en) 2004-03-16 2005-09-22 Medtronic, Inc. Intra-luminal device for gastrointestinal electrical stimulation
EP1753464A2 (en) 2004-03-26 2007-02-21 Quark Biotech, Inc. Annexin ii and uses thereof
JP4256294B2 (en) * 2004-03-31 2009-04-22 株式会社神戸製鋼所 Die plate
US7931661B2 (en) 2004-06-14 2011-04-26 Usgi Medical, Inc. Apparatus and methods for performing transluminal gastrointestinal procedures
US7225016B1 (en) 2004-06-16 2007-05-29 Pacesetter, Inc. Implantable medical device with nerve signal sensing
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US20060058852A1 (en) 2004-09-10 2006-03-16 Steve Koh Multi-variable feedback control of stimulation for inspiratory facilitation
US20060068452A1 (en) 2004-09-29 2006-03-30 Power3 Medical Products, Inc. Differential protein expression patterns related to disease states
US20060088862A1 (en) 2004-09-30 2006-04-27 Nancy Lee Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods, and kits thereof
US20060130161A1 (en) 2004-10-12 2006-06-15 Carantech, Inc. Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
WO2006079152A1 (en) 2004-10-20 2006-08-03 Resmed Limited Method and apparatus for detecting ineffective inspiratory efforts and improving patient-ventilator interaction
US20060115867A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. TRIM 5 related protein as a biomarker of neurodegenerative disease
US20060115854A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease
US20060115856A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. 2'-5'-oligoadenylate synthetase like protein as a biomarker for neurodegenerative disease
US20060115855A1 (en) 2004-12-01 2006-06-01 Power3 Medical Products, Inc. FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease
US20060121619A1 (en) 2004-12-02 2006-06-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis
US20060122661A1 (en) 2004-12-03 2006-06-08 Mandell Lee J Diaphragmatic pacing with activity monitor adjustment
US20060130833A1 (en) 2004-12-16 2006-06-22 Magdy Younes Treatment of obstructive sleep apnea
DE102006001780A1 (en) 2005-01-14 2006-08-24 Siemens Corp. Research, Inc. Method for diagnosis of amylotrophic lateral sclerosis, comprising surface-enhanced desorption-ionisation mass spectrometry of proteins from patients and analysing peak values on an alternating decision tree
US7729767B2 (en) 2005-02-15 2010-06-01 Baker Iii Rex M Implantable generating system
US20060270742A1 (en) 2005-05-02 2006-11-30 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
MX2007013980A (en) 2005-05-13 2008-01-14 Neurosignal Technologies Inc Method and system to control respiration by means of neuro-electrical coded signals.
US20070054852A1 (en) 2005-05-27 2007-03-08 Junyu Lin Compositions and methods of use of Semaphorin 3F and antagonists thereof in the stimulation of neuromuscular regeneration and treatment of muscular diseases
MX2007015006A (en) 2005-06-01 2008-03-18 Edison Pharmaceuticals Inc Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers.
US8364455B2 (en) 2005-06-09 2013-01-29 Maquet Critical Care Ab Simulator for use with a breathing-assist device
US8036750B2 (en) 2005-06-13 2011-10-11 Cardiac Pacemakers, Inc. System for neural control of respiration
US20070021500A1 (en) 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070017809A1 (en) 2005-07-21 2007-01-25 Power3 Medical Products, Inc. Assay for ALS and ALS-like disorders
US20070021421A1 (en) 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
PL2407486T3 (en) 2005-08-19 2018-05-30 Wyeth Llc Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
DK1933821T3 (en) 2005-09-15 2020-10-26 Ptc Therapeutics Inc Tail variants of redox-active therapeutics for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CN101454041B (en) 2005-09-20 2012-12-12 呼吸科技公司 Systems, methods and apparatus for respiratory support of a patient
WO2007047408A2 (en) 2005-10-12 2007-04-26 Pathologica, Llc. Promac signature application
CN101674862A (en) 2005-11-10 2010-03-17 电子核心公司 Electrical stimulation treatment of bronchial constriction
WO2007058938A2 (en) 2005-11-10 2007-05-24 Inspiration Medical, Inc. Diaphragm stimulation device
EP2371416B1 (en) 2005-11-18 2018-08-22 Respicardia, Inc. System to modulate phrenic nerve to prevent sleep apnea
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US20070150023A1 (en) * 2005-12-02 2007-06-28 Ignagni Anthony R Transvisceral neurostimulation mapping device and method
US20070202537A1 (en) 2005-12-05 2007-08-30 Prosetta Corporation Biomarkers for als
US7672728B2 (en) 2005-12-28 2010-03-02 Cardiac Pacemakers, Inc. Neural stimulator to treat sleep disordered breathing
US8281792B2 (en) * 2005-12-31 2012-10-09 John W Royalty Electromagnetic diaphragm assist device and method for assisting a diaphragm function
JP5264506B2 (en) 2006-01-19 2013-08-14 マケット・クリティカル・ケア・アーベー Device for dynamically determining respiratory characteristics of spontaneously breathing patients receiving mechanical breathing assistance
US7347695B2 (en) 2006-02-03 2008-03-25 Ware Linda M Chronic obstructive pulmonary disease simulator
US20070191908A1 (en) * 2006-02-16 2007-08-16 Jacob Doreen K Method and apparatus for stimulating a denervated muscle
US20070197932A1 (en) 2006-02-17 2007-08-23 Feke Gilbert T Non-invasive methods for evaluating retinal affecting neurodegenerative diseases
JP5374162B2 (en) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ, インコーポレイテッド Modulation of redox-activated therapeutic side chain variants and energy biomarkers for the treatment of mitochondrial diseases and other conditions
JP2009528059A (en) 2006-02-28 2009-08-06 メタボロン インコーポレイテッド Biomarkers for amyotrophic lateral sclerosis and methods of using them
US7810497B2 (en) 2006-03-20 2010-10-12 Ric Investments, Llc Ventilatory control system
US7900626B2 (en) * 2006-04-17 2011-03-08 Daly Robert W Method and system for controlling breathing
US20080039917A1 (en) 2006-04-28 2008-02-14 Cross Thomas E Implantable medical leads and lead assemblies with improved flexibility and extensibility to facilitate body movements
AU2007249811A1 (en) * 2006-05-11 2007-11-22 Avicena Group, Inc. Creatine-ligand compounds and methods of use thereof
EP2468272A1 (en) 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US20070282388A1 (en) 2006-06-01 2007-12-06 Reuven Sandyk Method and apparatus for treatment of amyotrophic lateral sclerosis patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6397108B1 (en) * 2000-04-03 2002-05-28 Medtronic Inc. Safety adaptor for temporary medical leads
US20050021102A1 (en) * 2003-07-23 2005-01-27 Ignagni Anthony R. System and method for conditioning a diaphragm of a patient

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
US8676323B2 (en) 2006-03-09 2014-03-18 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US9079016B2 (en) 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
US9820671B2 (en) 2007-05-17 2017-11-21 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
WO2009059033A1 (en) * 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US8478412B2 (en) 2007-10-30 2013-07-02 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US9138580B2 (en) 2007-10-30 2015-09-22 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system

Also Published As

Publication number Publication date
US20070265611A1 (en) 2007-11-15
US7962215B2 (en) 2011-06-14
EP1996284A2 (en) 2008-12-03
US8676323B2 (en) 2014-03-18
US20080125828A1 (en) 2008-05-29
WO2007103585A3 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
US7962215B2 (en) Ventilatory assist system and methods to improve respiratory function
JP7153373B2 (en) Diaphragmatic pacing system
US11357979B2 (en) Systems and methods for sensing and stimulation
US6251126B1 (en) Method and apparatus for synchronized treatment of obstructive sleep apnea
US6269269B1 (en) Method and apparatus for synchronized treatment of obstructive sleep apnea
US8406885B2 (en) System and method for conditioning a diaphragm of a patient
JP2021513449A (en) Ventilator and how to ventilate the patient
JP7184370B2 (en) Device for prevention, alleviation and/or treatment of cognitive impairment
US20220134095A1 (en) Systems and methods for strengthening a respiratory muscle
US20180008826A1 (en) System and method for activating inspiratory and expiratory muscle function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007752811

Country of ref document: EP